US20050033411A1 - Surface features of an implantable medical device - Google Patents

Surface features of an implantable medical device Download PDF

Info

Publication number
US20050033411A1
US20050033411A1 US10/911,968 US91196804A US2005033411A1 US 20050033411 A1 US20050033411 A1 US 20050033411A1 US 91196804 A US91196804 A US 91196804A US 2005033411 A1 US2005033411 A1 US 2005033411A1
Authority
US
United States
Prior art keywords
stent
asperities
layer
coating
roughness factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/911,968
Inventor
Steven Wu
Sameer Harish
Deborra Sanders-Millare
Judy Guruwaiya
Daryush Mirzaee
Syed Hossainy
Charlene Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/911,968 priority Critical patent/US20050033411A1/en
Publication of US20050033411A1 publication Critical patent/US20050033411A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0077Special surfaces of prostheses, e.g. for improving ingrowth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/848Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/91533Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0004Rounded shapes, e.g. with rounded corners
    • A61F2230/0013Horseshoe-shaped, e.g. crescent-shaped, C-shaped, U-shaped
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/901Method of manufacturing prosthetic device

Definitions

  • This invention relates to surface features of implantable medical devices, for example stents and grafts, and to methods for forming such surface features.
  • Percutaneous transluminal coronary angioplasty is a procedure for treating heart disease.
  • a catheter assembly having a balloon portion is introduced into the cardiovascular system of a patient via the brachial or femoral artery.
  • the catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion.
  • the balloon is inflated to a predetermined size to radially compress against and remodel the artery wall for dilating the lumen.
  • the balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.
  • a problem associated with the procedure includes formation of intimal flaps or torn arterial linings that can collapse and occlude the conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation.
  • an implantable device an example of which includes an expandable stent, is implanted in the lumen to maintain the vascular patency.
  • Stents are scaffoldings, usually cylindrical or tubular in shape, functioning to physically hold open, and if desired, to expand the wall of the passageway.
  • stents are compressed for insertion through small cavities via small catheters, and then expanded to a larger diameter once at the desired location.
  • Examples in patent literature disclosing stents include U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat. No. 4,800,882 issued to Gianturco, and U.S. Pat. No. 4,886,062 issued to Wiktor.
  • a problem encountered with intravascular stents is that, once implanted into the blood stream, platelets and other blood components tend to adhere to any portion of the stent surfaces having roughness or irregularity. Adhesion and aggregation of platelets and other blood components can lead to thrombosis and restenosis. Therefore, an important aspect of manufacturing and finishing stents is ensuring that all stent surfaces are made extremely smooth, without roughness and irregularities. This is accomplished by highly polishing the entire surface of the stent material, typically by electropolishing or by using an abrasive slurry, as described in U.S. Pat. No. 5,746,691 titled “Method for Polishing Surgical Stents” issued to Frantzen and U.S. Pat. No. 5,788,558 “Apparatus and method for Polishing Lumenal Prostheses” issued to Klein.
  • therapeutic substances can be administered.
  • anticoagulants, antiplatelets and cytostatic agents are commonly used to prevent thrombosis of the coronary lumen, to inhibit development of restenosis, and to reduce post-angioplasty proliferation of the vascular tissue, respectively.
  • systemic administration of these drugs often produces adverse or toxic side effects for the patient.
  • Local delivery is a highly suitable method of treatment in that smaller levels of medication, as compared to systemic dosages, are concentrated at a specific site. Local delivery therefore produces fewer side effects and achieves more effective results.
  • a well-known method for medicating stents involves the use of a polymeric carrier coated onto the body of the stent, as disclosed in U.S. Pat. No. 5,464,650 issued to Berg et al., U.S. Pat. No. 5,605,696 issued to Eury et al., U.S. Pat. No. 5,865,814 issued to Tuch, and U.S. Pat. No. 5,700,286 issued to Tartaglia et al.
  • the therapeutic substances are impregnated in, located on, or provided underneath the polymeric coating for release in situ once the stent has been implanted.
  • An obstacle often encountered with the use of stent coatings is poor adhesion of the polymeric coating to the surface of a stent.
  • a poorly adhering coating can be rubbed and peeled off of the stent if the coating contacts an arterial wall while the stent is being moved into position.
  • the distortion the stent undergoes as it expands can cause the coating to peel, crack, or tear, and disengage from the stent.
  • Poor adhesion of the coating material can promote thrombosis and restenosis, by providing additional surfaces for platelets and other blood components to adhere. Additionally, poor adhesion and loss of the coating also leads to loss of a significant amount of the drugs to be delivered from the coating.
  • Another technical challenge in using stent coatings to deliver drugs is loading enough drug onto the stent, so that an effective amount of the drug or drug combination is delivered to the treatment site.
  • the total amount of a drug that can be loaded onto a stent in a polymeric coating is limited by the amount of drug that can be mixed into the polymer (the concentration of the drug in the polymer), and the amount of polymer and drug mixture that can be coated onto the stent (the thickness of the coating on the stent for a given stent size). Therefore, a stent that carries more coating can deliver greater amounts of drugs.
  • increasing the thickness of a stent coating can be difficult, particularly if the coating does not adhere well to the stent material.
  • Controlled release can be achieved by coating a stent with a number of layers. For instance, each layer can contain a different drug or be made of a polymer that releases drugs at different rates.
  • additional layers tend to adhere poorly to underlying layers. The additional layers peel off either during application of the additional layer over an underlying layer, or, as described above, when the stent is delivered and expanded within the artery.
  • Another complication for drug delivery from a stent is that the arterial wall tissue the stent is compressed against can be tough and fibrotic, preventing medication released from the stent from penetrating the tissue in which the medication may be therapeutically beneficial.
  • An implantable medical device capable of delivering therapeutic substances from a coating is provided, which provides a high retention of one or more layers of coating material.
  • the implantable device also allows a greater total amount of coating to be carried by the device, allowing for greater amounts of therapeutic substances to be delivered from the device.
  • the implantable device can penetrate the arterial wall to enhance delivery of therapeutic substances into the arterial wall.
  • the implantable medical device has a generally tubular structure with an inner surface and an outer surface.
  • the outer surface has asperities on designated regions that have roughness factors, Ra, of greater than 40 nm.
  • the designated regions can be the entire outer surface, a middle section of the outer surface, or ends of the outer surface.
  • the inner surface is smooth.
  • the outer surface, or portion thereof can be coated with a coating containing a therapeutic substance or substances, a polymer, or a combination of therapeutic substances and polymer.
  • the coating can be made of one or more layers and the layers can hold different therapeutic substances, polymers, or combination of therapeutic substances and polymers.
  • the asperities may have surface protrusions and indentations of various shapes.
  • the asperities can have sharp tips, be rounded, be square, or a combination of these shapes.
  • Exemplary embodiments are made by polishing the inner surface of the implantable medical device and forming asperities on the designated region of the outer surface.
  • the inner surface is polished before the asperities are formed and the inner surface is protected while the asperities are being formed.
  • the asperities are formed by projecting grit, which can be beads or sand, at the designated region of the outer surface.
  • the asperities are formed by depositing material onto the designated region.
  • the material is deposited by adding particles to the designated region and bonding the particles, for instance by sintering, to the designated region.
  • the material is deposited by sputtering.
  • the material added to the outer surface is radio-opaque.
  • the asperities are formed by applying a chemical etchant to the designated region and rinsing the chemical etchant off of the region after a predetermined period of time.
  • the chemical etchant can by applied by sponging or spraying the etchant onto the outer surface.
  • a patterned mask which has openings, is applied to the outer surface and then the chemical etchant is applied, allowing the chemical etchant to etch through the openings.
  • the asperities are formed by machining or laser cutting.
  • FIG. 1A is a perspective view of an example of a stent in an expanded state.
  • FIG. 1B is a cross-sectional side view of a stent implanted in a lumen.
  • FIG. 1C is a side view of a graft.
  • FIG. 1D is a cross-sectional side view of a graft implanted in a damaged blood vessel.
  • FIG. 1E illustrates a portion of the struts of the stent of FIG. 1A , which shows depots formed therein.
  • FIG. 1F is a cross-sectional side view of a stent strut, taken in the direction of the arrows and along the plane of line 1 F- 1 F of FIG. 1E , illustrating a depot formed in strut.
  • FIG. 1G illustrates the strut of FIG. 1F in which a material has been deposited into the depot.
  • FIG. 2 graphically depicts elements used in determining the roughness factor, Ra, of a surface.
  • FIGS. 3A, 3B , 3 C, 3 D, 3 E, 3 F, and 3 G are cross-sectional views of portions of implantable medical devices with exemplary asperities.
  • FIGS. 3F and 3G also show depots.
  • FIG. 4A, 4B , 4 C, 4 D and 4 E are cross-sectional views of portions of implantable medical devices with exemplary asperities covered with a coating.
  • FIG. 4F is a cross-sectional view of a portion of a conventional implantable medical device that is coated.
  • FIG. 5A, 5B , 5 C, 5 D, and 5 E are cross-sectional views of portions of implantable medical devices with exemplary asperities covered with two or three layers of coatings.
  • FIG. 5F is a cross-sectional view of a portion of a conventional implantable medical device that has two layers of coating.
  • FIG. 5G is a cross-sectional view of a portion of an implantable medical device with exemplary asperities and a depot.
  • the depot contains a material and the material and the asperities are covered with a coating.
  • FIG. 6A is a schematic representation of the method of using a pressurized grit source to create asperities on the outer surface of a stent while protecting the inner surface of the stent.
  • FIG. 6B is a schematic representation of a stent having asperities on a middle portion.
  • FIG. 6C is a schematic representation of a stent having asperities adjacent to the ends of the stent.
  • FIGS. 7A and 7B are scanning electron micrograph photographs of portions of stent surfaces on which asperities have been created by bead blasting.
  • FIG. 8 is a perspective view of a portion of a stent with asperities on the top surface deposited by sputtering material onto the top surface.
  • FIGS. 1A and 1B illustrate an exemplary stent 100 in accordance with one embodiment.
  • Stents are scaffoldings, usually cylindrical or tubular in shape, which are inserted into an anatomical passageway and operate to physically hold open and, if desired, to expand or replace the wall of a passageway.
  • Stents are capable of being compressed for insertion through small cavities via balloon-catheters, positioned in a desired location, then expanded to a larger diameter.
  • Stents can be either balloon expandable or self-expanding.
  • exemplary stent 100 is a patterned tubular device that includes a plurality of radially expanding cylindrical struts 102 disposed generally coaxially and interconnected by connecting struts 104 that are disposed between and connect adjacent cylindrical struts 102 .
  • Struts 102 and 104 can be any suitable thickness T between the stent outer surface 110 and inner surface 112 .
  • thickness T is in the range of approximately 50 ⁇ m (0.002 inches) to 200 ⁇ m (0.008 inches). A specific choice of thickness depends on the anatomy and size of the target lumen.
  • FIG. 1B illustrates stent 100 of FIG. 1A implanted in a lumen 106 .
  • the stent struts 102 and 104 define a stent body having an outer surface 110 in contact with inner surface of the lumen 115 , and an inner surface 112 in contact with the fluid stream through the lumen 117 .
  • the outer surface is in contact with the blood vessel wall, and the inner surface is in contact with the blood flowing through the vessel.
  • FIG. 1C An exemplary graft 120 is illustrated in FIG. 1C .
  • Grafts are typically placed in a blood vessel to either replace a diseased segment that has been removed, or, as illustrated in FIG. 1D , to form a bypass conduit through a damaged segment of the vessel wall, for instance, an aneurysm 126 .
  • the graft 120 has a tubular portion 122 , which spans the site of the damaged tissue and through which the blood flows.
  • the graft has sections, 124 and 125 , at both ends of tube 122 that are used to secure the graft to the inside of the vessel wall 115 .
  • the graft also has an outer surface 130 , portions of which are in contact with inner surface of the blood vessel wall 115 , and an inner surface 132 , in contact with the blood flowing through the vessel 117 .
  • the implantable device may include a single depot, or a plurality of depots, formed in an outer surface thereof.
  • the materials may be filled, fully or partially, with a material, such as a therapeutic substance or polymer, as discussed below.
  • FIGS. 1E, 1F , and 1 G illustrate a portion of stent struts 102 , 104 of the exemplary stent 100 having depots 130 formed in an outer surface thereof.
  • Depots 130 which may also be referred to as a pores or a cavities, can be formed in virtually any implantable device structure.
  • Depots 130 are formed by a manufacturer at any preselected location and have any preselected depth, size, and geometrical configuration.
  • the location of depots 130 on the outer surface of the implantable device varies according to intended usage and application.
  • the depth and size of depots 130 typically depend on the material and dimensions of the implantable device, the type and amount of materials deposited within depot 130 , and the clinical purpose and usage of the device.
  • depots typically have a depth, D, that is between 10% and 90%, e.g. 40% to 60%, of the strut thickness, T (illustrated in FIG. 1F ).
  • the depth and size of the individual depots 130 formed on a single device can vary relative to one another.
  • Depots 130 may be formed in a variety of selected geometrical shapes including, but not limited to, generally cylindrical shapes, generally conical shapes, and elongated trenches.
  • depots 130 contain material 132 , as depicted in FIG. 1G .
  • Depots 130 may contain a material that is the same, or different than the device covering material, as described in detail below with respect to implantable medical device covers for delivering therapeutic substances.
  • asperities are created on a designated region or regions of the surface of the implantable devices.
  • the asperities cause the designated region to have a roughness factor, Ra, defined below, greater than about 40 nm (nanometers), which is the upper limit of roughness factors typical of polished stent surfaces.
  • the asperities so formed cause the designated region to have a roughness factor, Ra, greater than about 100 nm.
  • the inner surface of the implantable medical device which contacts the blood flowing through the vessel, to be smooth, in order to prevent aggregation of platelets from the blood on the stent.
  • the outer surface of the implantable devices, which contacts the arterial wall need not be smooth. Therefore, the designated region or regions having the asperities are typically on the outer surface of the implantable device.
  • a roughness factor, Ra is used to quantify the surface roughness.
  • a surface having asperities is outlined in two-dimensions by the profile 210 .
  • Profile 210 outlines the irregular protrusions 211 and indentations 212 of a surface having asperities.
  • the roughness factor, Ra is defined herein as the arithmetic mean of the absolute values of the profile departures 213 from a centerline 214 through profile 210 , within an evaluation length 215 .
  • centerline 214 becomes a mean plane
  • Ra is defined as the arithmetic mean of the absolute values of the surface departures from the mean plane within an evaluation area.
  • the roughness factor, Ra, of asperities on an implantable medical device within the present invention may be measured, for example, by using a commercially available Veeco Metrology Group (Tucson, Ariz.) WYKO NT-2000 system, which is a non-contact optical profiler.
  • VSI vertical scanning interferometer
  • a low pass filter is used which removes the effects of high spatial frequency roughness, smoothing over features that are smaller than a nine pixel window.
  • a 50 ⁇ objective and 2.0 ⁇ FOV converter sense are used to produce an effective magnification of 100 ⁇ . This objective and converter combination profiles a 0.58 ⁇ m ⁇ 0.44 ⁇ m evaluation area, at a spatial sampling interval of 159.13 nm. For statistical purposes, samples are measures at five separate locations. Equation 1 is used to calculate a value of Ra.
  • outer surface asperities in accordance with the present invention can have a variety of shapes, some examples of which are illustrated in FIGS. 3A-3E .
  • FIGS. 3A-3E illustrate cross-sectional views of portions of implantable devices (for example, portions of stent struts, 102 or 104 ) with average thicknesses 310 and inner surfaces 312 .
  • Outer surface asperities 314 can be random and irregular, as exemplified in FIGS. 3A and 3B .
  • the asperities 314 can also be more regular and well-defined, as exemplified in FIGS. 3C, 3D , and 3 E.
  • the asperities of the embodiments can be formed by protrusions and indentations in the surface that can have a variety of shapes and sizes, for example, the rounded shape 318 of FIG. 3B , the pointed shape 319 of FIG. 3D , or the rectangular shape 315 of FIG. 3E .
  • the protrusion and indentations cause the surface to have ridges 316 and channels 317 .
  • the protrusions and indentations can also have different densities on the surface, as illustrated by the difference between FIGS. 3C and 3D .
  • the asperities 314 may be formed on an implantable medical device that has depots 330 .
  • depots 330 have a greater depth than the asperities 314 .
  • the depot surface 333 may be smooth, as illustrated in FIG. 3F , or depot surface 333 may contain asperities 314 , as illustrated in FIG. 3G .
  • FIGS. 4A-4E illustrate coatings 401 covering the example surfaces illustrated in FIGS. 3A-3E .
  • Coating 401 may be, for example, a polymeric coating that contains a therapeutic substance, as described in detail below.
  • the asperities of the present invention provide a mechanical hold for the coating and help to prevent the coating from slipping or peeling off of the implantable device.
  • the asperities also provide greater surface area on the implantable device, increasing the amount of coating that can be put onto the surface.
  • the greater amount of coating allows the implantable device to carry more therapeutic substance, so more medicine can be delivered from the implantable device in situ.
  • the coating may fully cover the asperities or the peaks of the asperities may extend through the coating.
  • the asperities can also allow two or more layers of a coating to adhere to an implantable device, as illustrated in FIGS. 5A-5E .
  • a first layer 510 is coated onto the surface and then covered with a second layer, 512 , or even third layer 514 ( FIG. 5C ).
  • the first coating 510 partially fills the depth of the areas between the asperities, but the peaks of some or all of the asperities extend above the coating 510 .
  • the second (and third) layer can adhere to both the first layer and protruding implantable device material, as can be seen by comparison to a conventional smooth stent with two layers, FIG. 5F .
  • FIGS. 5A-5E can be used to achieve different therapeutic substance release profiles. For example, if it is desired to release two therapeutic substances sequentially, one followed by the other, two layers as illustrated in FIG. 5A, 5B , 5 D, and 5 E can be used. A therapeutic substance in the outer layer 510 will be released first, as the outer layer dissolves, and a therapeutic substance in the underlying layer 512 will be released after the outer layer 510 has wholly or partially dissolved. This release profile is sometimes referred to as a “late burst”, especially if the second therapeutic substance to be released (that in the underlying layer 512 ) is in a highly soluble form, for instance, pure crystalline form.
  • the underlying layer can be made of a material that does not adhere well to the surface, because the outer layer can be used to hold the underlying layer onto the implantable device. As shown in FIGS. 5A-5E , the outer layer 512 can adhere to portions of the surface not covered by the underlying layer, and thus act as a seal for an underlying layer.
  • the therapeutic substance release profile can be manipulated even further.
  • the coating layer 512 on the outer surface of the implantable device and over depots 330 will need to partially or wholly dissolve before the material 520 deposited in depots 330 is exposed and can begin to dissolve and release the therapeutic substance.
  • release of the material deposited in the depots 330 can be delayed by application of the coating layer 512 .
  • the asperities are sharp, having, for instance, sharp protrusions as in 319 , FIG. 3D , or sharp edges, they can also penetrate the tissue of the lumen once the implantable device is expanded. The penetration may enhance the ability of therapeutic substances released from the coating to reach target cells. Sharp asperities may also help to hold the implantable device in place in the lumen, which may be particularly useful with grafts, which need to be affixed to the lumen at the distal and proximal end of the damaged tissue. In these cases, the asperities can be formed on the distal and proximal ends of the graft.
  • a thin-walled, small diameter, cylindrical tube is cut to produce the desired stent pattern.
  • Cutting is typically accomplished through laser cutting, as described in U.S. Pat. No. 5,759,192 “Method and Apparatus for Direct Laser Cutting of Metal Stents” to Saunders, or chemical etching, as described in U.S. Pat. No. 6,056,776 “Expandable Stents and method of Making Same” to Lau et al.
  • Other methods of cutting stent lattice patterns can be used. Instead of cutting the pattern into a tube, the stent lattice pattern can be cut into on a flat sheet of material, which is then roll and joined in a cylindrical configuration.
  • the tube or flat sheet used to form the stent may be made of any suitable biocompatible material such as a metallic material or an alloy, examples of which include, but not limited to, stainless steel, “MP35N,” “MP20N,” elastinite (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
  • MP35N and MP20N are trade names for alloys of cobalt, nickel, chromium and molybdenum available from standard Press Steel Co., Jenkintown, Pa.
  • “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum.
  • MP20N consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
  • the stent also may be made from bioabsorbable or biostable polymers.
  • Descaling is typically accomplished by ultrasonically cleaning the stent in heated acid, as described in U.S. Pat. No. 5,759,192.
  • the stent is also polished so the stent surfaces are made as smooth as possible.
  • a cleaning or rinsing step usually with an alcohol solution, follows the polishing step to remove any of the polishing solution that may be left on the stent.
  • Another method that is used to manufacture stents is to mold the stent into the desired shape. This method is especially useful if the stent is made from a polymeric material. Polishing is sometimes done after molding to ensure smooth stent surfaces.
  • Depots 130 , 330 may be formed as a laser trench on the implantable device by exposing the surface to an energy discharge from a laser, such as an excimer laser. Alternative methods of forming such depots 130 , 330 include, but are not limited to, physical and chemical etching techniques. Techniques of laser fabrication or etching to form depots are well-known to one of ordinary skill in the art. Depots 130 , 330 may be added before or after the asperities are formed
  • the asperities may be added to the outer surface of the stent at any point in the stent manufacturing process, provided that subsequent processing does not remove the asperities desired in the completed stent.
  • the asperities on the stent outer surface are created after the stent has been polished.
  • the smooth inner surface is protected during creation of the asperities to preserve the smoothness of the inner surface. This may be done, for example, by inserting a mandrel or a hypo tube inside the stent or inserting and inflating a balloon inside the stent.
  • the inner surface can also be masked with a temporary protective coating, which is removed after the asperities have been added to the outer surface of the stent.
  • a poly vinyl alcohol (PVA) solution (80% by weight dissolved in hot water at 100° C.) can be applied to the inner surface with a syringe and allowed to air dry, and can be removed by soaking in water.
  • PVA poly vinyl alcohol
  • the asperities are created before the stent pattern is cut. In these cases, the asperities need to be preserved when the stent is cut, descaled, and polished, and therefore this embodiment works well with asperities that are not likely to be destroyed in subsequent processing. If subsequent processing might destroy the asperities, a temporary protective coating can be applied to the outer surface of the stent to preserve the asperities.
  • the asperities can be formed either before or after formation of the depots, depending on the methods used to form the depots and the asperities. In some methods, if the asperities are formed after the depots, the surface of the depots may also be roughened.
  • FIG. 6A illustrates one embodiment, in which a pressurized stream of grit material is directed upon the outer surface 110 of stent 100 to create asperities on the outer surface of the stent.
  • processes include bead blasting and sand blasting.
  • Bead blasting refers to the use of pressurized gas to project beads of a relatively uniform diameter at an object at a high velocity.
  • the bead may be made of a variety of materials, such as latex, aluminum oxide, or silicon oxide.
  • the grit projected does not have as uniform a diameter as in bead blasting. Both bead blasting and sand blasting are techniques that are well known in the art.
  • the stent 100 which has been polished, is mounted onto a mandrel 612 to protect the stent's inner surface during blasting.
  • the stent is then rotated while the grit 616 , e.g. beads, is projected at the stent outer surface from the pressurized grit source 618 .
  • the grit is projected at the stent at an approximately 30° angle 620 to the vertical axis of the stent, and is passed up and down over the outer surface 110 of the stent until the desired pattern, type, and number of asperities have been created.
  • the visual appearance of the surface can be used to indicate that it is roughened appropriately.
  • the outer surface of the stent is smooth, shiny, and reflective before the process, but becomes dull, non-reflective, and of a darker color shade after the roughening process. Subsequently, the stent is removed from the mandrel and cleaned, for example by immersion and sonication in an isopropyl alcohol bath for approximately 20 minutes.
  • the roughness factor achieved using a pressurized grit source can be controlled by the size of the grit, e.g., the diameter of the beads, the pressure used, the distance between the grit source and the stent surface, and the length of time the grit is blasted at the surface.
  • the grit can be beads having a diameter of between 10 ⁇ m and 50 ⁇ m. Pressures of 30 PSI (pounds per square inch) to 60 PSI can be used to project the beads from a distance of approximately 3-10 cm from the stent.
  • the grit source is passed very quickly, in approximately 1-3 seconds, down and up over the stent outer surface.
  • the stent is then rotated 120° and the process repeated twice so the entire stent is roughened.
  • Average roughness values achieved are typically in a range of 100 nm to 300 nm, and usefully in a range of 130 nm to 210 nm.
  • the entire outer surface need not be roughened.
  • the grit may be projected at only a middle region 624 ( FIGS. 6A and 6B ) of the stent, so that the asperities are formed only in a middle region of the stent's outer surface, and not adjacent to the opposing ends of the stent, FIG. 6B .
  • the grit may be projected only at the ends of the stent, to create asperities at one or both ends, 625 and 626 .
  • the depots may be in regions where there are asperities, may be in regions where there are not asperities, or both.
  • FIGS. 7A and 7B are scanning electron micrograph photographs of portions of stent struts (e.g. 102 of FIG. 1A ) having asperities created by bead blasting (as described above).
  • the stent material in the examples shown in the photographs is 316L stainless steel.
  • the photographs show the outer surface of the struts, which have been roughened.
  • the asperities in FIG. 7A were created using a pressure of 60 PSI, and the asperities in FIG. 7B were created using a pressure of 30 PSI.
  • the photographs also show the surfaces of the sides of the struts, which were also roughened during the bead blasting process.
  • the sides of the struts may be left smooth or asperities can be added to only a portion thereof.
  • the asperities may be formed by grinding the tubular stent between two sanding plates or using sandpaper to scratch the outer surface.
  • the roughness factor achieved depends on the grain size of the surface of the sanding plates.
  • This method may be particularly useful with polymer stents or stents made from relatively soft materials. Typically, this method is used to create asperities after the stent pattern has been cut into the hypotube (or cut into a flat piece of material and the material rolled into a tube), and after the stent has been descaled, if descaling is necessary, and polished.
  • chemical etching is used to create asperities on the outer surface of a stent.
  • Chemical etching methods are known to those of ordinary skill in the art.
  • the chemical etchant solution typically includes an acid that degrades and dissolves the material from which the stent is made.
  • the chemical etchant is applied to the outer surface, and then rinsed off of the surface after a predetermined period of time. The length of time the etchant is left on the surface depends on the etch rate and the depth of etch desired.
  • the roughness factor produced by the chemical etchant depends on the method of application of the etchant.
  • the chemical etchant is applied to the stent outer surface with a fine sponge or by spraying a mist of the chemical etchant onto the stent.
  • a temporary protective coating e.g., poly vinyl alcohol dissolved in water, is applied to the inner surface of the stent to protect the inner surface from the etchant to keep the inner surface smooth.
  • the chemical etchant is rinsed off of the stent, leaving a rough outer surface.
  • the roughness factor will depend on the stent material and the chemical etchant used, the amount and length of time the etchant was applied, and how the etchant was applied.
  • the stent is made of a composite material where one of the components of the composite material can be easily dissolved by the chemical etchant.
  • a metal alloy such as stainless steel can be used to form the stent and nitric acid can be applied to the outer surface to create the asperities.
  • a hydrochloric acid solution 37% by volume in water, can also be used to create the asperities.
  • a patterned mask that has openings is applied to the stent outer surface before the chemical etchant is applied.
  • the etchant is then applied in a uniform manner and allowed to etch the stent material through the openings of the mask.
  • the use of patterned masks with chemical etchants is known to those of ordinary skill in the art. Because it is usually easier to mask and etch a flat piece of material than a hypo-tube, the mask is typically applied to a flat piece of the stent material and the resulting outer surface pattern etched into the surface. Then, the flat piece of stent material is cut, rolled and joined into a stent.
  • the flat piece of stent material may be polished before the mask and etch process, so that the asperities created by the mask and etch are not degraded in a subsequent polishing process.
  • a cutting process that does not leave scrap between the stent struts can be used to eliminate the descaling step, which may also damage the asperities.
  • the stent pattern can be cut using another chemical etching step where the second mask, which protects the asperities, is in the pattern of the stent and the etchant is allowed to dissolve all material not masked.
  • the patterned mask can be used to make asperities that are composed of more regular and well-defined shapes.
  • the shapes can be chosen depending on the eventual application of the stent.
  • a patterned masking followed by etching is used to create asperities composed of relatively sharp tips ( 319 of FIG. 3D ), or ridges and channels ( 316 and 317 , respectively, of FIG. 3E ).
  • the sharp tips 319 can have a height between 0.1 ⁇ m and 10 ⁇ m.
  • the sharp tips can be of any density on the surface, although a higher density produces more surface area, provides better mechanical hold of the coating, and has more tips to penetrate the tissue.
  • the asperities made by this method typically have a roughness factor between 50 nm and 5 ⁇ m.
  • a thicker material can be used to form the stent.
  • the finished stent has the desired strut thickness T after etching so that the structural integrity of the stent is not compromised by creating the asperities.
  • asperities are formed by machining or laser cutting the outer surface. These methods can also be used to make asperities composed of more regular and well-defined shapes. For example, a laser discharge machine tool can be programmed to cut a desired pattern into the outer surface of a stent.
  • a thicker material can be used to form the stent, resulting in a completed stent having the desired average strut thickness.
  • additional material is deposited onto the outer surface of the stent to create the asperities.
  • the additional material which is typically a metal
  • the additional material is first made into a powder.
  • the powder particles are then bonded to the outer surface to form the asperities.
  • the powder can be made, for example, by grinding the metal to form particles of a predetermined size.
  • the particles are then put onto the outer surface of the stent, for example, by rolling the stent in the powdered metal or spaying the powdered metal onto the stent.
  • the stent can be electrostatically charged to a charge, typically negative, that is opposite that of the powdered metal, to improve the adhesion of the powder to the stent.
  • the stent coated with the particles is then heated to weld the particles to the stent by methods, for example sintering in a furnace or with a flame, known to those of skill in the art.
  • the stent material, particle material, and sintering temperature are chosen so that melting temperatures of the materials allow the particles to be welded to the stent without distortion of the stent by the heat treatment.
  • the stent material may be 316L stainless steel and the particles may be gold, aluminum, or copper.
  • the sintering temperature would have to be below the melting temperature of 316L stainless steel, 1388° C.
  • the inner surface can be protected by inserting a mandrel or applying a temporary coating to the inner surface that prevents the particles from contacting and staying on the inner surface when they are applied to the stent.
  • the coating typically a polymeric material, will burn off of the stent in the subsequent heat treatment.
  • the temporary coating can also be used on the outer surface of the stent if it is desired to create asperities on only designated regions of the outer surface. For example, if it is desired to have the asperities adjacent to the ends of the stent (as illustrated in FIG. 6B ), the temporary coating can be applied to the middle portion of the stent before the particles are applied to the stent.
  • the roughness factor, Ra, achieved using this method depends on the size of the particles in the powder and is in the range of 50 nm to 5 ⁇ m.
  • the additional material may also be added via physical deposition processes, for example, sputtering, which is known to those of ordinary skill in the art.
  • sputtering an energy beam, for instance an ion beam, is directed at a target formed of the material which is to be deposited on the substrate.
  • the energy beam dislodges atoms of the target material.
  • the target material atoms are transported to the substrate, which in this instance is the stent on which asperities are being formed.
  • the atoms form “islands”, or small nodules of the deposition material on the substrate.
  • FIG. 8 illustrates the “islands” 812 formed on an illustrative portion of the substrate 810 , corresponding to the stent outer surface ( 310 of FIG. 3 ).
  • sputtering is used to form a thin film of the deposition material over the substrate, and sputtering conditions are used such that the “islands” grow, spread, and condense on the substrate to form a thin film.
  • the sputtering process conditions are set so that instead of creating a uniform film over the substrate, the “islands” do not grow, spread, and condense, leaving a rough surface. Process conditions in which a lower pressure and shorter deposition time than is typically used for thin film deposition are used to form the asperities.
  • a cut stent is inserted into the sputtering chamber, with inner surface protected, and rotated while material is deposited on the outer surface.
  • material can be deposited onto the hypo-tube before the stent pattern is cut into it, or flat piece of stent material before it is cut and rolled into stent. If the subsequent processing of the stent will destroy the added asperities, a temporary protective coating can be applied to protect them.
  • the sputtering may only loosely deposit the material onto the outer surface of the stent.
  • a heat treatment for instance sintering can be performed.
  • the temperature ranges for heating will depend on the deposition material and the stent material.
  • the roughness factor achieved in this embodiment will have a lower value of approximately 50 nm and an upper value of approximately 200 nm.
  • material is added to the outer surface after the stent is polished, although it can be done at any point in the process provided the subsequent processes do not remove the asperities. This will again depend on the material that is used to manufacture stent and the material deposited on the stent.
  • radiopaque materials are deposited on the stent, to not only create asperities on the stent, but to allow visualization of the stent after implantation.
  • the radio-opaque material can be applied adjacent to the ends of the stent.
  • an implantable medical device with a therapeutic substance or substance, or with a polymer containing one or more therapeutic substances are known to one of ordinary skill in the art.
  • One or more therapeutic substances can be added to an implantable medical device by dissolving or mixing the therapeutic substances in a solvent and applying the therapeutic substance and solvent mixture to the implantable medical device.
  • a solution of the polymeric material and one or more therapeutic substances are mixed, often with a solvent, and the polymer mixture is applied to the implantable device.
  • An implantable device can also be coated with a polymer which does not contain a therapeutic substance, for example, to form a sealant layer over an underlying layer, which does contain a therapeutic substance.
  • Methods of applying the therapeutic substance, polymer, or therapeutic substance and polymer mixture to the implantable medical device are known to those of skill in the art. Methods include, but are not limited to, immersion, spray-coating, sputtering, and gas-phase polymerization. Immersion, or dip-coating, entails submerging the entire implantable device, or an entire section of the implantable device, in the mixture. The implantable device is then dried, for instance in a vacuum or oven, to evaporate the solvent, leaving the therapeutic substance or therapeutic substance and polymer coating on the implantable device. Similarly, spray-coating requires enveloping the entire device, or an entire section of the device, in a large cloud of the mixture, and then allowing the solvent to evaporate, to leave the coating.
  • Sputtering typically involves placing a polymeric coating material target in an environment, and applying energy to the target such that polymeric material is emitted from the target. The polymer emitted deposits onto the device, forming a coating.
  • gas phase polymerization typically entails applying energy to a monomer in the gas phase within a system set up such that the polymer formed is attracted to a stent, thereby creating a coating around the stent.
  • the implantable device contains depots ( 130 of FIGS. 1E, 1F , and 1 G), it is desirable to first deposit material ( 132 of FIG. 1G ) into the depots before coating the outer surface of the device.
  • Materials deposited into the depots are similar to those used to cover the device, and include, for example polymers, therapeutic substances, or combination thereof.
  • Materials 132 may be deposited into depots using any suitable method.
  • material 132 is added to a first solvent.
  • Material 132 is dispersed throughout the first solvent so that material 132 is in a true solution, saturated or supersaturated with the first solvent or suspended in fine particles in the first solvent.
  • the first solvent can be virtually any solvent that is compatible with material 132 .
  • a high capillary permeation and a viscosity not greater than about ten centipoise allows the first solvent to penetrate into depots 130 more quickly, eliminating a requirement to apply the first solvent to the implantable device for a prolonged period of time.
  • first solvents include, but are not limited to, acetone, ethanol, methanol, isopropanol, tetrahydrofuran, and ethyl acetate.
  • the first solvent containing material 132 is applied to the implantable device, for example by immersing or spraying the solvent using procedures that are well-known to one having ordinary skill in the art.
  • the first solvent containing material 132 is applied for a predetermined period of time, the specific time depending on the capillary permeation and viscosity of the first solvent, the volume of depots 130 , and the amount of material 132 to be deposited.
  • the first solvent containing material 132 After applying the first solvent containing material 132 for a selected duration, the first solvent is removed from the implantable device using conventional techniques, such as evaporation in ambient pressure, room temperature and anhydrous atmosphere and/or by exposure to mild heat (e.g., 60° C.) under vacuum condition.
  • the implantable device typically has a clustered or gross formation of material 132 gathered on the body surface. The cluster is generally removed by immersing the device in a non-solvent and agitating the implantable device via mechanical perturbation techniques, such as vortexing or vigorous shaking.
  • the non-solvent can have a low capillary permeation or a contact angle greater than about 90° and a viscosity not less than about 0.5 centipoise so that the second fluid is not capable of significantly penetrating into depots 130 during the process of agitation.
  • a suitable non-solvent include, but are not limited to, saturated hydrocarbons or alkanes, such as hexane, heptane, and octane.
  • the implantable device is rinsed in a second solvent to facilitate dissolution of material 132 .
  • the second solvent generally has a low capillary permeation and a viscosity of not less than about 1.0 centipoise and is therefore incapable of significantly penetrating into depots 130 during the rinsing stage.
  • the rinsing is conducted rapidly for example in a range from 1 second to about 15 seconds, the exact duration depending on the solubility of material 132 in the second solvent. Extended duration of exposure of the implantable device to the second solvent may lead to the penetration of the second solvent into depots 130 .
  • the rinsing step is repeated, if desired, until all traces of material 132 are removed from the surface of the implantable device.
  • the second solvent removes excess material 132 from the surface of the implantable device body.
  • second solvents include, but are not limited to, dimethylsulfoxide (DMSO), water, DMSO in an aqueous solution, glyme, and glycerol.
  • DMSO dimethylsulfoxide
  • the second solvent is removed from the implantable device body using conventional techniques.
  • the first and second solvents as well as the non-solvent are selected to not adversely affect the characteristics and composition of material 132 . Although one method of depositing material 132 into depots 130 has been described here, depots 130 may be filled using any suitable method.
  • a coating can be applied to the outer surface of the implantable device, as described above.
  • the polymer used for coating the implantable device and filling depots is typically either bioabsorbable or biostable.
  • a bioabsorbable polymer bio-degrades or breaks down in the body and is not present sufficiently long after implantation to cause an adverse local response.
  • Bioabsorbable polymers are gradually absorbed or eliminated by the body by hydrolysis, metabolic process, bulk, or surface erosion.
  • bioabsorbable, biodegradable materials include but are not limited to polycaprolactone (PCL), poly-D, L-lactic acid (DL-PLA), poly-L-lactic acid (L-PLA), poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolic acid-cotrimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly (amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters), polyalkylene oxalates, polyphosphazenes, polyiminocarbonates, and aliphatic polycarbonates.
  • PCL polycaprolactone
  • DL-PLA L-lactic acid
  • L-PLA poly-L-lactic acid
  • L-PLA poly(l
  • Biomolecules such as heparin, fibrin, fibrinogen, cellulose, starch, and collagen are typically also suitable.
  • biostable polymers include Parylene®, Parylast®, polyurethane (for example, segmented polyurethanes such as Biospan®), polyethylene, polyethlyene teraphthalate, ethylene vinyl acetate, silicone and polyethylene oxide.
  • Therapeutic substances can include, but are not limited to, antineoplastic, antimitotic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antiproliferative, antibiotic, antioxidant, and antiallergic substances as well as combinations thereof.
  • antineoplastics and/or antimitotics include paclitaxel (e.g., TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g., Taxoteree from Aventis S.
  • antiplatelets examples include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors
  • doxorubicin hydrochloride e.g., Adriamycin® from Pharmacia & Upjohn, Peapack N.J.
  • mitomycin e.g., Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.
  • antiplatelets examples include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost,
  • an antiallergic agent is permirolast potassium.
  • Other therapeutic substances or agents that may be used include alpha-interferon, genetically engineered epithelial cells, and dexamethasone.
  • the therapeutic substance is a radioactive isotope for implantable device usage in radiotherapeutic procedures.
  • radioactive isotopes include, but are not limited to, phosphoric acid (H 3 P 32 O 4 ), palladium (Pd 103 ), cesium (Cs 131 ), and iodine (I 125 ). While the preventative and treatment properties of the foregoing therapeutic substances or agents are well-known to those of ordinary skill in the art, the substances or agents are provided by way of example and are not meant to be limiting. Other therapeutic substances are equally applicable for use with the disclosed methods and compositions.
  • the following example illustrates a method for creating asperities on an outer surface of a stent, and then coating the stent. The results are compared to the result obtained for a stent coated in the same manner but without a roughened outer surface.
  • the example is given by way of illustration and not limitation.
  • Stents # 1-5 were fabricated by cutting, descaling, and polishing a 316L stainless steel hypo-tube as described in U.S. Pat. No. 5,759,192.
  • the inner surface of stents # 1-#4 were protected by inserting a mandrel, hypotube, or inflated balloon into the interior of the stent to protect the inner surface.
  • the outer surface of each stent was bead blasted, using bead diameters in the range of 10 ⁇ m to 50 ⁇ m.
  • Stents #1 and #2 were bead blasted at 60 PSI pressure and stents #3 and #4 were bead blasted at 30 PSI pressure, as indicated in Table 1. Bead blasting was done at a distance of approximately 5 cm from the stent.
  • stents # 1-# 4 were cleaned by immersion in an ultrasonic isopropyl alcohol bath for 20 minutes and allowed to dry.
  • Stent #5 was also cleaned in an ultrasonic isoproply alcohol bath for 20 minutes and allowed to dry. Uncoated stents #1-#5 were weighed.
  • a coating solution was made by adding EVOH (ethylene vinyl alcohol copolymer) to DMSO (dimethysulfoxide) in a weight ratio of 1:4 EVOH:DMSO. Tetrahydrofuran (THF) was added to the EVOH:DMSO solution. Tetrahydrofuran constituted 20% by weight of the total weight of the solution. The solution was vortexed and placed in a tube. Stents #1-#5 were each dipped into the solution. The coated stents were passed over a hot plate, for about 3-5 seconds, with a temperature setting of about 60° C. The coated stents were cured in a convection over at 60° C. for one hour.
  • EVOH ethylene vinyl alcohol copolymer
  • DMSO dimethyl methysulfoxide
  • the coating stents were then re-dipped into the solution, passed again over the hot plate as above and cured in the convention over at 60° C. for four hours.
  • the coated stents were weighed and the weight difference between the coated and non-coated stent was calculated. The results are shown in Table 1 below.
  • stents # 1-# 5 were expanded on a balloon and examined visually with a microscope. No peeling or defects in the stent coatings were observed.

Abstract

An implantable medical device, such as a stent or graft, having asperities on a designated region of its outer surface is disclosed. The asperities can serve to improve retention of one or more layers of a coating on the device and to increase the amount of coating that can be carried by the device. The asperities can be formed by using a stream of pressurized grit to roughen the surface. The asperities can also be formed by removing material from the outer surface, for example, by chemical etching with or without a patterned mask. Alternatively, the asperities can be formed by adding material to the outer surface, for example, by welding powder particles to the outer surface or sputtering.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention relates to surface features of implantable medical devices, for example stents and grafts, and to methods for forming such surface features.
  • 2. Description of the Background
  • Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against and remodel the artery wall for dilating the lumen. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.
  • A problem associated with the procedure includes formation of intimal flaps or torn arterial linings that can collapse and occlude the conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the chance of the development of thrombosis and restenosis, an implantable device, an example of which includes an expandable stent, is implanted in the lumen to maintain the vascular patency. Stents are scaffoldings, usually cylindrical or tubular in shape, functioning to physically hold open, and if desired, to expand the wall of the passageway. Typically stents are compressed for insertion through small cavities via small catheters, and then expanded to a larger diameter once at the desired location. Examples in patent literature disclosing stents include U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat. No. 4,800,882 issued to Gianturco, and U.S. Pat. No. 4,886,062 issued to Wiktor.
  • A problem encountered with intravascular stents is that, once implanted into the blood stream, platelets and other blood components tend to adhere to any portion of the stent surfaces having roughness or irregularity. Adhesion and aggregation of platelets and other blood components can lead to thrombosis and restenosis. Therefore, an important aspect of manufacturing and finishing stents is ensuring that all stent surfaces are made extremely smooth, without roughness and irregularities. This is accomplished by highly polishing the entire surface of the stent material, typically by electropolishing or by using an abrasive slurry, as described in U.S. Pat. No. 5,746,691 titled “Method for Polishing Surgical Stents” issued to Frantzen and U.S. Pat. No. 5,788,558 “Apparatus and method for Polishing Lumenal Prostheses” issued to Klein.
  • To further fight against thrombosis and restenosis, and in treating the damaged vascular tissue, therapeutic substances can be administered. For example, anticoagulants, antiplatelets and cytostatic agents are commonly used to prevent thrombosis of the coronary lumen, to inhibit development of restenosis, and to reduce post-angioplasty proliferation of the vascular tissue, respectively. To provide an efficacious concentration to the treated site, systemic administration of these drugs often produces adverse or toxic side effects for the patient. Local delivery is a highly suitable method of treatment in that smaller levels of medication, as compared to systemic dosages, are concentrated at a specific site. Local delivery therefore produces fewer side effects and achieves more effective results.
  • One commonly applied technique for the local delivery of therapeutic substances is through the use of medicated stents. A well-known method for medicating stents involves the use of a polymeric carrier coated onto the body of the stent, as disclosed in U.S. Pat. No. 5,464,650 issued to Berg et al., U.S. Pat. No. 5,605,696 issued to Eury et al., U.S. Pat. No. 5,865,814 issued to Tuch, and U.S. Pat. No. 5,700,286 issued to Tartaglia et al. The therapeutic substances are impregnated in, located on, or provided underneath the polymeric coating for release in situ once the stent has been implanted.
  • An obstacle often encountered with the use of stent coatings is poor adhesion of the polymeric coating to the surface of a stent. During stent delivery, a poorly adhering coating can be rubbed and peeled off of the stent if the coating contacts an arterial wall while the stent is being moved into position. Also, when a coated stent is expanded in situ, the distortion the stent undergoes as it expands can cause the coating to peel, crack, or tear, and disengage from the stent. Poor adhesion of the coating material can promote thrombosis and restenosis, by providing additional surfaces for platelets and other blood components to adhere. Additionally, poor adhesion and loss of the coating also leads to loss of a significant amount of the drugs to be delivered from the coating.
  • Another technical challenge in using stent coatings to deliver drugs is loading enough drug onto the stent, so that an effective amount of the drug or drug combination is delivered to the treatment site. The total amount of a drug that can be loaded onto a stent in a polymeric coating is limited by the amount of drug that can be mixed into the polymer (the concentration of the drug in the polymer), and the amount of polymer and drug mixture that can be coated onto the stent (the thickness of the coating on the stent for a given stent size). Therefore, a stent that carries more coating can deliver greater amounts of drugs. However, increasing the thickness of a stent coating can be difficult, particularly if the coating does not adhere well to the stent material.
  • When delivering drugs from a stent, it is also desirable to control the timing and rate of release of the drugs being delivered. Controlled release can be achieved by coating a stent with a number of layers. For instance, each layer can contain a different drug or be made of a polymer that releases drugs at different rates. However, additional layers tend to adhere poorly to underlying layers. The additional layers peel off either during application of the additional layer over an underlying layer, or, as described above, when the stent is delivered and expanded within the artery.
  • Another complication for drug delivery from a stent is that the arterial wall tissue the stent is compressed against can be tough and fibrotic, preventing medication released from the stent from penetrating the tissue in which the medication may be therapeutically beneficial.
  • SUMMARY
  • An implantable medical device capable of delivering therapeutic substances from a coating is provided, which provides a high retention of one or more layers of coating material. The implantable device also allows a greater total amount of coating to be carried by the device, allowing for greater amounts of therapeutic substances to be delivered from the device. In some embodiments the implantable device can penetrate the arterial wall to enhance delivery of therapeutic substances into the arterial wall.
  • In one embodiment within the present invention, the implantable medical device has a generally tubular structure with an inner surface and an outer surface. The outer surface has asperities on designated regions that have roughness factors, Ra, of greater than 40 nm. The designated regions can be the entire outer surface, a middle section of the outer surface, or ends of the outer surface. Typically, the inner surface is smooth.
  • In various embodiments, the outer surface, or portion thereof, can be coated with a coating containing a therapeutic substance or substances, a polymer, or a combination of therapeutic substances and polymer. The coating can be made of one or more layers and the layers can hold different therapeutic substances, polymers, or combination of therapeutic substances and polymers.
  • The asperities may have surface protrusions and indentations of various shapes. In some embodiments, the asperities can have sharp tips, be rounded, be square, or a combination of these shapes.
  • Exemplary embodiments are made by polishing the inner surface of the implantable medical device and forming asperities on the designated region of the outer surface. In some embodiments, the inner surface is polished before the asperities are formed and the inner surface is protected while the asperities are being formed.
  • In some embodiments, the asperities are formed by projecting grit, which can be beads or sand, at the designated region of the outer surface.
  • In some embodiments, the asperities are formed by depositing material onto the designated region. In one method, the material is deposited by adding particles to the designated region and bonding the particles, for instance by sintering, to the designated region. In one method, the material is deposited by sputtering. In some embodiments, the material added to the outer surface is radio-opaque.
  • In some embodiments, the asperities are formed by applying a chemical etchant to the designated region and rinsing the chemical etchant off of the region after a predetermined period of time. The chemical etchant can by applied by sponging or spraying the etchant onto the outer surface. In some embodiments, a patterned mask, which has openings, is applied to the outer surface and then the chemical etchant is applied, allowing the chemical etchant to etch through the openings.
  • In some embodiments, the asperities are formed by machining or laser cutting.
  • These and other features and aspects of the various embodiments of the present invention may be better understood in view of the drawings and the following detailed description.
  • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1A is a perspective view of an example of a stent in an expanded state.
  • FIG. 1B is a cross-sectional side view of a stent implanted in a lumen.
  • FIG. 1C is a side view of a graft.
  • FIG. 1D is a cross-sectional side view of a graft implanted in a damaged blood vessel.
  • FIG. 1E illustrates a portion of the struts of the stent of FIG. 1A, which shows depots formed therein.
  • FIG. 1F is a cross-sectional side view of a stent strut, taken in the direction of the arrows and along the plane of line 1F-1F of FIG. 1E, illustrating a depot formed in strut.
  • FIG. 1G illustrates the strut of FIG. 1F in which a material has been deposited into the depot.
  • FIG. 2 graphically depicts elements used in determining the roughness factor, Ra, of a surface.
  • FIGS. 3A, 3B, 3C, 3D, 3E, 3F, and 3G are cross-sectional views of portions of implantable medical devices with exemplary asperities. FIGS. 3F and 3G also show depots.
  • FIG. 4A, 4B, 4C, 4D and 4E are cross-sectional views of portions of implantable medical devices with exemplary asperities covered with a coating.
  • FIG. 4F is a cross-sectional view of a portion of a conventional implantable medical device that is coated.
  • FIG. 5A, 5B, 5C, 5D, and 5E are cross-sectional views of portions of implantable medical devices with exemplary asperities covered with two or three layers of coatings.
  • FIG. 5F is a cross-sectional view of a portion of a conventional implantable medical device that has two layers of coating.
  • FIG. 5G is a cross-sectional view of a portion of an implantable medical device with exemplary asperities and a depot. The depot contains a material and the material and the asperities are covered with a coating.
  • FIG. 6A is a schematic representation of the method of using a pressurized grit source to create asperities on the outer surface of a stent while protecting the inner surface of the stent.
  • FIG. 6B is a schematic representation of a stent having asperities on a middle portion.
  • FIG. 6C is a schematic representation of a stent having asperities adjacent to the ends of the stent.
  • FIGS. 7A and 7B are scanning electron micrograph photographs of portions of stent surfaces on which asperities have been created by bead blasting.
  • FIG. 8 is a perspective view of a portion of a stent with asperities on the top surface deposited by sputtering material onto the top surface.
  • DETAILED DESCRIPTION
  • The present invention includes surface treatments for implantable medical devices, such as stents and grafts, often referred to as endoprostheses. FIGS. 1A and 1B illustrate an exemplary stent 100 in accordance with one embodiment. Stents are scaffoldings, usually cylindrical or tubular in shape, which are inserted into an anatomical passageway and operate to physically hold open and, if desired, to expand or replace the wall of a passageway. Stents are capable of being compressed for insertion through small cavities via balloon-catheters, positioned in a desired location, then expanded to a larger diameter. Stents can be either balloon expandable or self-expanding.
  • Referring to FIG. 1A, exemplary stent 100 is a patterned tubular device that includes a plurality of radially expanding cylindrical struts 102 disposed generally coaxially and interconnected by connecting struts 104 that are disposed between and connect adjacent cylindrical struts 102. Struts 102 and 104 can be any suitable thickness T between the stent outer surface 110 and inner surface 112. Typically thickness T is in the range of approximately 50 μm (0.002 inches) to 200 μm (0.008 inches). A specific choice of thickness depends on the anatomy and size of the target lumen.
  • FIG. 1B illustrates stent 100 of FIG. 1A implanted in a lumen 106. The stent struts 102 and 104 define a stent body having an outer surface 110 in contact with inner surface of the lumen 115, and an inner surface 112 in contact with the fluid stream through the lumen 117. For example, when stent 100 is implanted in a blood vessel, the outer surface is in contact with the blood vessel wall, and the inner surface is in contact with the blood flowing through the vessel.
  • An exemplary graft 120 is illustrated in FIG. 1C. Grafts are typically placed in a blood vessel to either replace a diseased segment that has been removed, or, as illustrated in FIG. 1D, to form a bypass conduit through a damaged segment of the vessel wall, for instance, an aneurysm 126. The graft 120 has a tubular portion 122, which spans the site of the damaged tissue and through which the blood flows. The graft has sections, 124 and 125, at both ends of tube 122 that are used to secure the graft to the inside of the vessel wall 115. The graft also has an outer surface 130, portions of which are in contact with inner surface of the blood vessel wall 115, and an inner surface 132, in contact with the blood flowing through the vessel 117.
  • In some embodiments, the implantable device may include a single depot, or a plurality of depots, formed in an outer surface thereof. The materials may be filled, fully or partially, with a material, such as a therapeutic substance or polymer, as discussed below.
  • FIGS. 1E, 1F, and 1G illustrate a portion of stent struts 102, 104 of the exemplary stent 100 having depots 130 formed in an outer surface thereof. Depots 130, which may also be referred to as a pores or a cavities, can be formed in virtually any implantable device structure. Depots 130 are formed by a manufacturer at any preselected location and have any preselected depth, size, and geometrical configuration. The location of depots 130 on the outer surface of the implantable device varies according to intended usage and application. The depth and size of depots 130 typically depend on the material and dimensions of the implantable device, the type and amount of materials deposited within depot 130, and the clinical purpose and usage of the device. Typically, depots have a depth, D, that is between 10% and 90%, e.g. 40% to 60%, of the strut thickness, T (illustrated in FIG. 1F). The depth and size of the individual depots 130 formed on a single device can vary relative to one another. Depots 130 may be formed in a variety of selected geometrical shapes including, but not limited to, generally cylindrical shapes, generally conical shapes, and elongated trenches.
  • In some embodiments, depots 130 contain material 132, as depicted in FIG. 1G. Depots 130 may contain a material that is the same, or different than the device covering material, as described in detail below with respect to implantable medical device covers for delivering therapeutic substances.
  • The conventional practice of having highly polished implantable medical device surfaces contributes to the poor adhesion problem and other problems mentioned above that are associated with coatings used on implantable devices and drug delivery from such coatings. Therefore, in accordance with the present invention, asperities are created on a designated region or regions of the surface of the implantable devices. The asperities cause the designated region to have a roughness factor, Ra, defined below, greater than about 40 nm (nanometers), which is the upper limit of roughness factors typical of polished stent surfaces. Typically, the asperities so formed cause the designated region to have a roughness factor, Ra, greater than about 100 nm.
  • It is often desirable for the inner surface of the implantable medical device, which contacts the blood flowing through the vessel, to be smooth, in order to prevent aggregation of platelets from the blood on the stent. The outer surface of the implantable devices, which contacts the arterial wall, need not be smooth. Therefore, the designated region or regions having the asperities are typically on the outer surface of the implantable device.
  • A roughness factor, Ra, is used to quantify the surface roughness. In FIG. 2, a surface having asperities is outlined in two-dimensions by the profile 210. Profile 210 outlines the irregular protrusions 211 and indentations 212 of a surface having asperities. The roughness factor, Ra, is defined herein as the arithmetic mean of the absolute values of the profile departures 213 from a centerline 214 through profile 210, within an evaluation length 215. For a three-dimensional surface, centerline 214 becomes a mean plane and Ra is defined as the arithmetic mean of the absolute values of the surface departures from the mean plane within an evaluation area. The digital approximation for the three-dimensional Ra over an evaluation area is given in Equation 1: R a = 1 MN j = 1 M i = 1 N Z ji Equation 1
    M and N are the number of data points in the X and Y directions, respectively, of the evaluation area, and Z is the surface height of each point relative to the mean plane.
  • The roughness factor, Ra, of asperities on an implantable medical device within the present invention may be measured, for example, by using a commercially available Veeco Metrology Group (Tucson, Ariz.) WYKO NT-2000 system, which is a non-contact optical profiler. VSI (vertical scanning interferometer) mode is used. For cylindrical implantable medical devices, such as stents, cylinder and tilt terms are removed so the stent surface appears flat. A low pass filter is used which removes the effects of high spatial frequency roughness, smoothing over features that are smaller than a nine pixel window. A 50× objective and 2.0× FOV converter sense are used to produce an effective magnification of 100×. This objective and converter combination profiles a 0.58 μm×0.44 μm evaluation area, at a spatial sampling interval of 159.13 nm. For statistical purposes, samples are measures at five separate locations. Equation 1 is used to calculate a value of Ra.
  • In general, outer surface asperities in accordance with the present invention can have a variety of shapes, some examples of which are illustrated in FIGS. 3A-3E. FIGS. 3A-3E illustrate cross-sectional views of portions of implantable devices (for example, portions of stent struts, 102 or 104) with average thicknesses 310 and inner surfaces 312. Outer surface asperities 314 can be random and irregular, as exemplified in FIGS. 3A and 3B. The asperities 314 can also be more regular and well-defined, as exemplified in FIGS. 3C, 3D, and 3E. The asperities of the embodiments can be formed by protrusions and indentations in the surface that can have a variety of shapes and sizes, for example, the rounded shape 318 of FIG. 3B, the pointed shape 319 of FIG. 3D, or the rectangular shape 315 of FIG. 3E. In the exemplary surface of FIG. 3E, the protrusion and indentations cause the surface to have ridges 316 and channels 317. The protrusions and indentations can also have different densities on the surface, as illustrated by the difference between FIGS. 3C and 3D.
  • As illustrated by the exemplary surfaces in FIGS. 3F and 3G, the asperities 314 may be formed on an implantable medical device that has depots 330. Note that depots 330 have a greater depth than the asperities 314. The depot surface 333 may be smooth, as illustrated in FIG. 3F, or depot surface 333 may contain asperities 314, as illustrated in FIG. 3G.
  • FIGS. 4A-4E illustrate coatings 401 covering the example surfaces illustrated in FIGS. 3A-3E. Coating 401 may be, for example, a polymeric coating that contains a therapeutic substance, as described in detail below. As compared to the coated smooth surface 410 (FIG. 4F) of a conventional coated implantable medical device, the asperities of the present invention provide a mechanical hold for the coating and help to prevent the coating from slipping or peeling off of the implantable device. The asperities also provide greater surface area on the implantable device, increasing the amount of coating that can be put onto the surface. The greater amount of coating allows the implantable device to carry more therapeutic substance, so more medicine can be delivered from the implantable device in situ. The coating may fully cover the asperities or the peaks of the asperities may extend through the coating.
  • The asperities can also allow two or more layers of a coating to adhere to an implantable device, as illustrated in FIGS. 5A-5E. A first layer 510 is coated onto the surface and then covered with a second layer, 512, or even third layer 514 (FIG. 5C). The first coating 510 partially fills the depth of the areas between the asperities, but the peaks of some or all of the asperities extend above the coating 510. Because of the asperities, the second (and third) layer can adhere to both the first layer and protruding implantable device material, as can be seen by comparison to a conventional smooth stent with two layers, FIG. 5F.
  • The multiple coating layers of FIGS. 5A-5E can be used to achieve different therapeutic substance release profiles. For example, if it is desired to release two therapeutic substances sequentially, one followed by the other, two layers as illustrated in FIG. 5A, 5B, 5D, and 5E can be used. A therapeutic substance in the outer layer 510 will be released first, as the outer layer dissolves, and a therapeutic substance in the underlying layer 512 will be released after the outer layer 510 has wholly or partially dissolved. This release profile is sometimes referred to as a “late burst”, especially if the second therapeutic substance to be released (that in the underlying layer 512) is in a highly soluble form, for instance, pure crystalline form. It should also be noted that, in accordance with the present invention, the underlying layer can be made of a material that does not adhere well to the surface, because the outer layer can be used to hold the underlying layer onto the implantable device. As shown in FIGS. 5A-5E, the outer layer 512 can adhere to portions of the surface not covered by the underlying layer, and thus act as a seal for an underlying layer.
  • If the implantable device contains depots 330 (as illustrated in FIG. 5G), the therapeutic substance release profile can be manipulated even further. The coating layer 512 on the outer surface of the implantable device and over depots 330 will need to partially or wholly dissolve before the material 520 deposited in depots 330 is exposed and can begin to dissolve and release the therapeutic substance. Thus, release of the material deposited in the depots 330 can be delayed by application of the coating layer 512.
  • If the asperities are sharp, having, for instance, sharp protrusions as in 319, FIG. 3D, or sharp edges, they can also penetrate the tissue of the lumen once the implantable device is expanded. The penetration may enhance the ability of therapeutic substances released from the coating to reach target cells. Sharp asperities may also help to hold the implantable device in place in the lumen, which may be particularly useful with grafts, which need to be affixed to the lumen at the distal and proximal end of the damaged tissue. In these cases, the asperities can be formed on the distal and proximal ends of the graft.
  • In the discussion that follows, methods are described for forming asperities on the outer surface of a stent, as an example of an implantable medical device. It is to be understood that, in accordance with the invention, these methods can be applied to any implantable medical device, including grafts and other implantable devices.
  • In one method for manufacturing a stent, a thin-walled, small diameter, cylindrical tube is cut to produce the desired stent pattern. Cutting is typically accomplished through laser cutting, as described in U.S. Pat. No. 5,759,192 “Method and Apparatus for Direct Laser Cutting of Metal Stents” to Saunders, or chemical etching, as described in U.S. Pat. No. 6,056,776 “Expandable Stents and method of Making Same” to Lau et al. Other methods of cutting stent lattice patterns can be used. Instead of cutting the pattern into a tube, the stent lattice pattern can be cut into on a flat sheet of material, which is then roll and joined in a cylindrical configuration.
  • The tube or flat sheet used to form the stent may be made of any suitable biocompatible material such as a metallic material or an alloy, examples of which include, but not limited to, stainless steel, “MP35N,” “MP20N,” elastinite (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. The stent also may be made from bioabsorbable or biostable polymers.
  • Often, cutting the stent lattice pattern, especially by laser, leaves scrap that must be removed, in a process known as descaling, to reveal the lattice pattern of the stent. Descaling is typically accomplished by ultrasonically cleaning the stent in heated acid, as described in U.S. Pat. No. 5,759,192. The stent is also polished so the stent surfaces are made as smooth as possible. In conventional processes, a cleaning or rinsing step, usually with an alcohol solution, follows the polishing step to remove any of the polishing solution that may be left on the stent.
  • Another method that is used to manufacture stents is to mold the stent into the desired shape. This method is especially useful if the stent is made from a polymeric material. Polishing is sometimes done after molding to ensure smooth stent surfaces.
  • Depots 130, 330 may be formed as a laser trench on the implantable device by exposing the surface to an energy discharge from a laser, such as an excimer laser. Alternative methods of forming such depots 130, 330 include, but are not limited to, physical and chemical etching techniques. Techniques of laser fabrication or etching to form depots are well-known to one of ordinary skill in the art. Depots 130, 330 may be added before or after the asperities are formed
  • In general, the asperities may be added to the outer surface of the stent at any point in the stent manufacturing process, provided that subsequent processing does not remove the asperities desired in the completed stent.
  • For example, in one embodiment, the asperities on the stent outer surface are created after the stent has been polished. In this case the smooth inner surface is protected during creation of the asperities to preserve the smoothness of the inner surface. This may be done, for example, by inserting a mandrel or a hypo tube inside the stent or inserting and inflating a balloon inside the stent. The inner surface can also be masked with a temporary protective coating, which is removed after the asperities have been added to the outer surface of the stent. For example, a poly vinyl alcohol (PVA) solution (80% by weight dissolved in hot water at 100° C.) can be applied to the inner surface with a syringe and allowed to air dry, and can be removed by soaking in water. In another embodiment, the asperities are created before the stent pattern is cut. In these cases, the asperities need to be preserved when the stent is cut, descaled, and polished, and therefore this embodiment works well with asperities that are not likely to be destroyed in subsequent processing. If subsequent processing might destroy the asperities, a temporary protective coating can be applied to the outer surface of the stent to preserve the asperities.
  • If the stent contains depots, the asperities can be formed either before or after formation of the depots, depending on the methods used to form the depots and the asperities. In some methods, if the asperities are formed after the depots, the surface of the depots may also be roughened.
  • Methods of Treating the Surface
  • A. Mechanical Methods for Creating Asperities
  • A variety of methods can be used to create the asperities on the outer surface of the stent. FIG. 6A illustrates one embodiment, in which a pressurized stream of grit material is directed upon the outer surface 110 of stent 100 to create asperities on the outer surface of the stent. Examples of such processes include bead blasting and sand blasting. Bead blasting refers to the use of pressurized gas to project beads of a relatively uniform diameter at an object at a high velocity. The bead may be made of a variety of materials, such as latex, aluminum oxide, or silicon oxide. In sand blasting, the grit projected does not have as uniform a diameter as in bead blasting. Both bead blasting and sand blasting are techniques that are well known in the art.
  • In FIG. 6A, the stent 100, which has been polished, is mounted onto a mandrel 612 to protect the stent's inner surface during blasting. The stent is then rotated while the grit 616, e.g. beads, is projected at the stent outer surface from the pressurized grit source 618. The grit is projected at the stent at an approximately 30° angle 620 to the vertical axis of the stent, and is passed up and down over the outer surface 110 of the stent until the desired pattern, type, and number of asperities have been created. The visual appearance of the surface can be used to indicate that it is roughened appropriately. The outer surface of the stent is smooth, shiny, and reflective before the process, but becomes dull, non-reflective, and of a darker color shade after the roughening process. Subsequently, the stent is removed from the mandrel and cleaned, for example by immersion and sonication in an isopropyl alcohol bath for approximately 20 minutes.
  • The roughness factor achieved using a pressurized grit source can be controlled by the size of the grit, e.g., the diameter of the beads, the pressure used, the distance between the grit source and the stent surface, and the length of time the grit is blasted at the surface. By way of example and not limitation, the grit can be beads having a diameter of between 10 μm and 50 μm. Pressures of 30 PSI (pounds per square inch) to 60 PSI can be used to project the beads from a distance of approximately 3-10 cm from the stent. The grit source is passed very quickly, in approximately 1-3 seconds, down and up over the stent outer surface. The stent is then rotated 120° and the process repeated twice so the entire stent is roughened.
  • Average roughness values achieved are typically in a range of 100 nm to 300 nm, and usefully in a range of 130 nm to 210 nm.
  • Note also, that the entire outer surface need not be roughened. For example, the grit may be projected at only a middle region 624 (FIGS. 6A and 6B) of the stent, so that the asperities are formed only in a middle region of the stent's outer surface, and not adjacent to the opposing ends of the stent, FIG. 6B. Or, as illustrated in FIG. 6C, the grit may be projected only at the ends of the stent, to create asperities at one or both ends, 625 and 626.
  • If the stent contains depots, the depots may be in regions where there are asperities, may be in regions where there are not asperities, or both.
  • FIGS. 7A and 7B are scanning electron micrograph photographs of portions of stent struts (e.g. 102 of FIG. 1A) having asperities created by bead blasting (as described above). The stent material in the examples shown in the photographs is 316L stainless steel. The photographs show the outer surface of the struts, which have been roughened. The asperities in FIG. 7A were created using a pressure of 60 PSI, and the asperities in FIG. 7B were created using a pressure of 30 PSI. The photographs also show the surfaces of the sides of the struts, which were also roughened during the bead blasting process. In other embodiments, the sides of the struts may be left smooth or asperities can be added to only a portion thereof.
  • In another embodiment, the asperities may be formed by grinding the tubular stent between two sanding plates or using sandpaper to scratch the outer surface. In this method, the roughness factor achieved depends on the grain size of the surface of the sanding plates. This method may be particularly useful with polymer stents or stents made from relatively soft materials. Typically, this method is used to create asperities after the stent pattern has been cut into the hypotube (or cut into a flat piece of material and the material rolled into a tube), and after the stent has been descaled, if descaling is necessary, and polished.
  • B. Creating Asperities by Removal of Stent Material
  • In another embodiment, chemical etching is used to create asperities on the outer surface of a stent. Chemical etching methods are known to those of ordinary skill in the art. The chemical etchant solution typically includes an acid that degrades and dissolves the material from which the stent is made. The chemical etchant is applied to the outer surface, and then rinsed off of the surface after a predetermined period of time. The length of time the etchant is left on the surface depends on the etch rate and the depth of etch desired.
  • The roughness factor produced by the chemical etchant depends on the method of application of the etchant. In one embodiment, the chemical etchant is applied to the stent outer surface with a fine sponge or by spraying a mist of the chemical etchant onto the stent. A temporary protective coating, e.g., poly vinyl alcohol dissolved in water, is applied to the inner surface of the stent to protect the inner surface from the etchant to keep the inner surface smooth. The chemical etchant is rinsed off of the stent, leaving a rough outer surface. The roughness factor will depend on the stent material and the chemical etchant used, the amount and length of time the etchant was applied, and how the etchant was applied.
  • In one embodiment, the stent is made of a composite material where one of the components of the composite material can be easily dissolved by the chemical etchant. For example, a metal alloy, such as stainless steel can be used to form the stent and nitric acid can be applied to the outer surface to create the asperities. A hydrochloric acid solution, 37% by volume in water, can also be used to create the asperities.
  • In another embodiment, a patterned mask that has openings is applied to the stent outer surface before the chemical etchant is applied. The etchant is then applied in a uniform manner and allowed to etch the stent material through the openings of the mask. The use of patterned masks with chemical etchants is known to those of ordinary skill in the art. Because it is usually easier to mask and etch a flat piece of material than a hypo-tube, the mask is typically applied to a flat piece of the stent material and the resulting outer surface pattern etched into the surface. Then, the flat piece of stent material is cut, rolled and joined into a stent. The flat piece of stent material may be polished before the mask and etch process, so that the asperities created by the mask and etch are not degraded in a subsequent polishing process. Additionally, a cutting process that does not leave scrap between the stent struts can be used to eliminate the descaling step, which may also damage the asperities. For example, the stent pattern can be cut using another chemical etching step where the second mask, which protects the asperities, is in the pattern of the stent and the etchant is allowed to dissolve all material not masked.
  • In this embodiment, the patterned mask can be used to make asperities that are composed of more regular and well-defined shapes. The shapes can be chosen depending on the eventual application of the stent. In one example, a patterned masking followed by etching is used to create asperities composed of relatively sharp tips (319 of FIG. 3D), or ridges and channels (316 and 317, respectively, of FIG. 3E). The sharp tips 319 can have a height between 0.1 μm and 10 μm. The sharp tips can be of any density on the surface, although a higher density produces more surface area, provides better mechanical hold of the coating, and has more tips to penetrate the tissue. The asperities made by this method typically have a roughness factor between 50 nm and 5 μm.
  • If, when creating the asperities by chemical etching, a significant amount of stent material will be removed, for instance to reduce the average thickness T of the stent strut by more than 10%, a thicker material can be used to form the stent.
  • Therefore, the finished stent has the desired strut thickness T after etching so that the structural integrity of the stent is not compromised by creating the asperities.
  • In other embodiments, asperities are formed by machining or laser cutting the outer surface. These methods can also be used to make asperities composed of more regular and well-defined shapes. For example, a laser discharge machine tool can be programmed to cut a desired pattern into the outer surface of a stent.
  • Because machining and laser cutting will typically remove material from the stent, a thicker material can be used to form the stent, resulting in a completed stent having the desired average strut thickness.
  • C. Creating Asperities by Adding Material
  • In another embodiment, additional material is deposited onto the outer surface of the stent to create the asperities. In one method, the additional material, which is typically a metal, is first made into a powder. The powder particles are then bonded to the outer surface to form the asperities. The powder can be made, for example, by grinding the metal to form particles of a predetermined size. The particles are then put onto the outer surface of the stent, for example, by rolling the stent in the powdered metal or spaying the powdered metal onto the stent. The stent can be electrostatically charged to a charge, typically negative, that is opposite that of the powdered metal, to improve the adhesion of the powder to the stent.
  • The stent coated with the particles is then heated to weld the particles to the stent by methods, for example sintering in a furnace or with a flame, known to those of skill in the art. Typically, the stent material, particle material, and sintering temperature are chosen so that melting temperatures of the materials allow the particles to be welded to the stent without distortion of the stent by the heat treatment. For example, the stent material may be 316L stainless steel and the particles may be gold, aluminum, or copper. The sintering temperature would have to be below the melting temperature of 316L stainless steel, 1388° C.
  • In this method, the inner surface can be protected by inserting a mandrel or applying a temporary coating to the inner surface that prevents the particles from contacting and staying on the inner surface when they are applied to the stent. The coating, typically a polymeric material, will burn off of the stent in the subsequent heat treatment. The temporary coating can also be used on the outer surface of the stent if it is desired to create asperities on only designated regions of the outer surface. For example, if it is desired to have the asperities adjacent to the ends of the stent (as illustrated in FIG. 6B), the temporary coating can be applied to the middle portion of the stent before the particles are applied to the stent.
  • The roughness factor, Ra, achieved using this method depends on the size of the particles in the powder and is in the range of 50 nm to 5 μm.
  • The additional material may also be added via physical deposition processes, for example, sputtering, which is known to those of ordinary skill in the art. In sputtering, an energy beam, for instance an ion beam, is directed at a target formed of the material which is to be deposited on the substrate. The energy beam dislodges atoms of the target material. The target material atoms are transported to the substrate, which in this instance is the stent on which asperities are being formed. Once at the substrate, the atoms form “islands”, or small nodules of the deposition material on the substrate. FIG. 8 illustrates the “islands” 812 formed on an illustrative portion of the substrate 810, corresponding to the stent outer surface (310 of FIG. 3).
  • Conventionally, sputtering is used to form a thin film of the deposition material over the substrate, and sputtering conditions are used such that the “islands” grow, spread, and condense on the substrate to form a thin film. To form the asperities, however, the sputtering process conditions are set so that instead of creating a uniform film over the substrate, the “islands” do not grow, spread, and condense, leaving a rough surface. Process conditions in which a lower pressure and shorter deposition time than is typically used for thin film deposition are used to form the asperities.
  • Typically, a cut stent is inserted into the sputtering chamber, with inner surface protected, and rotated while material is deposited on the outer surface. Alternatively, material can be deposited onto the hypo-tube before the stent pattern is cut into it, or flat piece of stent material before it is cut and rolled into stent. If the subsequent processing of the stent will destroy the added asperities, a temporary protective coating can be applied to protect them.
  • The sputtering, however, may only loosely deposit the material onto the outer surface of the stent. In such cases, to further enhance attachment of the deposited material to the substrate, a heat treatment, for instance sintering can be performed. As discussed above, the temperature ranges for heating will depend on the deposition material and the stent material. The roughness factor achieved in this embodiment will have a lower value of approximately 50 nm and an upper value of approximately 200 nm.
  • Typically, material is added to the outer surface after the stent is polished, although it can be done at any point in the process provided the subsequent processes do not remove the asperities. This will again depend on the material that is used to manufacture stent and the material deposited on the stent.
  • In one embodiment, radiopaque materials are deposited on the stent, to not only create asperities on the stent, but to allow visualization of the stent after implantation. For example, the radio-opaque material can be applied adjacent to the ends of the stent.
  • Coatings for Delivering Therapeutic Substances
  • Methods of coating an implantable medical device with a therapeutic substance or substance, or with a polymer containing one or more therapeutic substances are known to one of ordinary skill in the art. One or more therapeutic substances can be added to an implantable medical device by dissolving or mixing the therapeutic substances in a solvent and applying the therapeutic substance and solvent mixture to the implantable medical device. To cover the implantable device with a polymer containing the therapeutic substance or substance combination, a solution of the polymeric material and one or more therapeutic substances are mixed, often with a solvent, and the polymer mixture is applied to the implantable device. An implantable device can also be coated with a polymer which does not contain a therapeutic substance, for example, to form a sealant layer over an underlying layer, which does contain a therapeutic substance.
  • Methods of applying the therapeutic substance, polymer, or therapeutic substance and polymer mixture to the implantable medical device are known to those of skill in the art. Methods include, but are not limited to, immersion, spray-coating, sputtering, and gas-phase polymerization. Immersion, or dip-coating, entails submerging the entire implantable device, or an entire section of the implantable device, in the mixture. The implantable device is then dried, for instance in a vacuum or oven, to evaporate the solvent, leaving the therapeutic substance or therapeutic substance and polymer coating on the implantable device. Similarly, spray-coating requires enveloping the entire device, or an entire section of the device, in a large cloud of the mixture, and then allowing the solvent to evaporate, to leave the coating. Sputtering typically involves placing a polymeric coating material target in an environment, and applying energy to the target such that polymeric material is emitted from the target. The polymer emitted deposits onto the device, forming a coating. Similarly, gas phase polymerization typically entails applying energy to a monomer in the gas phase within a system set up such that the polymer formed is attracted to a stent, thereby creating a coating around the stent.
  • If the implantable device contains depots (130 of FIGS. 1E, 1F, and 1G), it is desirable to first deposit material (132 of FIG. 1G) into the depots before coating the outer surface of the device. Materials deposited into the depots are similar to those used to cover the device, and include, for example polymers, therapeutic substances, or combination thereof.
  • Materials 132 may be deposited into depots using any suitable method. In an exemplary method of depositing material 132 into depots 130, material 132 is added to a first solvent. Material 132 is dispersed throughout the first solvent so that material 132 is in a true solution, saturated or supersaturated with the first solvent or suspended in fine particles in the first solvent. The first solvent can be virtually any solvent that is compatible with material 132. A high capillary permeation and a viscosity not greater than about ten centipoise allows the first solvent to penetrate into depots 130 more quickly, eliminating a requirement to apply the first solvent to the implantable device for a prolonged period of time. Examples of suitable first solvents include, but are not limited to, acetone, ethanol, methanol, isopropanol, tetrahydrofuran, and ethyl acetate. The first solvent containing material 132 is applied to the implantable device, for example by immersing or spraying the solvent using procedures that are well-known to one having ordinary skill in the art. The first solvent containing material 132 is applied for a predetermined period of time, the specific time depending on the capillary permeation and viscosity of the first solvent, the volume of depots 130, and the amount of material 132 to be deposited.
  • After applying the first solvent containing material 132 for a selected duration, the first solvent is removed from the implantable device using conventional techniques, such as evaporation in ambient pressure, room temperature and anhydrous atmosphere and/or by exposure to mild heat (e.g., 60° C.) under vacuum condition. The implantable device typically has a clustered or gross formation of material 132 gathered on the body surface. The cluster is generally removed by immersing the device in a non-solvent and agitating the implantable device via mechanical perturbation techniques, such as vortexing or vigorous shaking. The non-solvent can have a low capillary permeation or a contact angle greater than about 90° and a viscosity not less than about 0.5 centipoise so that the second fluid is not capable of significantly penetrating into depots 130 during the process of agitation. Examples of a suitable non-solvent include, but are not limited to, saturated hydrocarbons or alkanes, such as hexane, heptane, and octane.
  • The implantable device is rinsed in a second solvent to facilitate dissolution of material 132. The second solvent generally has a low capillary permeation and a viscosity of not less than about 1.0 centipoise and is therefore incapable of significantly penetrating into depots 130 during the rinsing stage. The rinsing is conducted rapidly for example in a range from 1 second to about 15 seconds, the exact duration depending on the solubility of material 132 in the second solvent. Extended duration of exposure of the implantable device to the second solvent may lead to the penetration of the second solvent into depots 130. The rinsing step is repeated, if desired, until all traces of material 132 are removed from the surface of the implantable device. The second solvent removes excess material 132 from the surface of the implantable device body. Useful examples of second solvents include, but are not limited to, dimethylsulfoxide (DMSO), water, DMSO in an aqueous solution, glyme, and glycerol. The second solvent is removed from the implantable device body using conventional techniques. The first and second solvents as well as the non-solvent are selected to not adversely affect the characteristics and composition of material 132. Although one method of depositing material 132 into depots 130 has been described here, depots 130 may be filled using any suitable method.
  • Once the depots have been filled, a coating can be applied to the outer surface of the implantable device, as described above.
  • The polymer used for coating the implantable device and filling depots is typically either bioabsorbable or biostable. A bioabsorbable polymer bio-degrades or breaks down in the body and is not present sufficiently long after implantation to cause an adverse local response. Bioabsorbable polymers are gradually absorbed or eliminated by the body by hydrolysis, metabolic process, bulk, or surface erosion. Examples of bioabsorbable, biodegradable materials include but are not limited to polycaprolactone (PCL), poly-D, L-lactic acid (DL-PLA), poly-L-lactic acid (L-PLA), poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolic acid-cotrimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly (amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters), polyalkylene oxalates, polyphosphazenes, polyiminocarbonates, and aliphatic polycarbonates. Biomolecules such as heparin, fibrin, fibrinogen, cellulose, starch, and collagen are typically also suitable. Examples of biostable polymers include Parylene®, Parylast®, polyurethane (for example, segmented polyurethanes such as Biospan®), polyethylene, polyethlyene teraphthalate, ethylene vinyl acetate, silicone and polyethylene oxide.
  • Therapeutic substances can include, but are not limited to, antineoplastic, antimitotic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antiproliferative, antibiotic, antioxidant, and antiallergic substances as well as combinations thereof. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g., TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g., Taxoteree from Aventis S. A., Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g., Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g., Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.) Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as Angiomax™ (Biogen, Inc., Cambridge, Mass.) Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g., Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g., Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.); calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suranin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents that may be used include alpha-interferon, genetically engineered epithelial cells, and dexamethasone. In other examples, the therapeutic substance is a radioactive isotope for implantable device usage in radiotherapeutic procedures. Examples of radioactive isotopes include, but are not limited to, phosphoric acid (H3P32O4), palladium (Pd103), cesium (Cs131), and iodine (I125). While the preventative and treatment properties of the foregoing therapeutic substances or agents are well-known to those of ordinary skill in the art, the substances or agents are provided by way of example and are not meant to be limiting. Other therapeutic substances are equally applicable for use with the disclosed methods and compositions.
  • The following example illustrates a method for creating asperities on an outer surface of a stent, and then coating the stent. The results are compared to the result obtained for a stent coated in the same manner but without a roughened outer surface. The example is given by way of illustration and not limitation.
  • EXAMPLE
  • Stents # 1-5 were fabricated by cutting, descaling, and polishing a 316L stainless steel hypo-tube as described in U.S. Pat. No. 5,759,192. The inner surface of stents # 1-#4 were protected by inserting a mandrel, hypotube, or inflated balloon into the interior of the stent to protect the inner surface. The outer surface of each stent was bead blasted, using bead diameters in the range of 10 μm to 50 μm. Stents #1 and #2 were bead blasted at 60 PSI pressure and stents #3 and #4 were bead blasted at 30 PSI pressure, as indicated in Table 1. Bead blasting was done at a distance of approximately 5 cm from the stent. The beads were passed very quickly, in approximately 1-3 seconds, down and up over the stent outer surface. The stent was then rotated 120° and the process repeated twice so the entire stent was roughened. After bead blasting, stents # 1-# 4 were cleaned by immersion in an ultrasonic isopropyl alcohol bath for 20 minutes and allowed to dry. Stent #5 was also cleaned in an ultrasonic isoproply alcohol bath for 20 minutes and allowed to dry. Uncoated stents #1-#5 were weighed.
  • A coating solution was made by adding EVOH (ethylene vinyl alcohol copolymer) to DMSO (dimethysulfoxide) in a weight ratio of 1:4 EVOH:DMSO. Tetrahydrofuran (THF) was added to the EVOH:DMSO solution. Tetrahydrofuran constituted 20% by weight of the total weight of the solution. The solution was vortexed and placed in a tube. Stents #1-#5 were each dipped into the solution. The coated stents were passed over a hot plate, for about 3-5 seconds, with a temperature setting of about 60° C. The coated stents were cured in a convection over at 60° C. for one hour. The coating stents were then re-dipped into the solution, passed again over the hot plate as above and cured in the convention over at 60° C. for four hours. The coated stents were weighed and the weight difference between the coated and non-coated stent was calculated. The results are shown in Table 1 below. For the stents #1-#4 the amount of coating on the stent is greater than that of stent #5.
    Pressure Used Weight difference between
    in Bead coated and uncoated stent
    Stent Blast (PSI) (weight of coating) (mg)
    #1 60 0.187
    #2 60 0.160
    #3 30 0.168
    #4 30 0.158
    #5 none 0.090
  • To test the adherence of the coating, stents # 1-# 5 were expanded on a balloon and examined visually with a microscope. No peeling or defects in the stent coatings were observed.
  • While particular embodiments of the present invention have been shown and described, it will be clear to those of ordinary skill in the art that changes and modifications can be made without departing from this invention in its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

Claims (40)

1-21. (canceled).
22. An implantable medical device comprising a substrate having an outer surface, the outer surface including asperities on a designated region of the outer surface so as to provide for a roughness factor greater than 40 nm.
23. The device of claim 22, wherein the substrate is a generally tubular structure having an inner surface opposite the outer surface, and the inner surface having a roughness factor less than 40 nm.
24. The device of claim 22, wherein the a roughness factor is greater than 100 nm.
25. The device of claim 22, wherein the designated region comprises the entire outer surface.
26. The device of claim 22, wherein the designated region comprises a portion of the outer surface in only a middle section of the device.
27. The device of claim 22, wherein the asperities are formed by material deposited on the outer surface of the device.
28. The device of claim 27, wherein the material is radioopaque.
29. The device of claim 22, wherein the asperities comprise sharp tips.
30. The device of claim 22, further comprising a layer of a material overlaying the asperities of the designated region of the outer surface.
31. The device of claim 30, wherein the layer comprises a therapeutic substance.
32. The device of claim 22, wherein the device is a stent or a graft.
33. The device of claim 22, wherein the device further comprises a plurality of depots in the outer surface, and wherein a layer of material fills the depots and covers the asperities, the material comprising a therapeutic substance.
34. A stent comprising a generally tubular structure having a surface with a roughness factor greater than 40 nm.
35. The stent of claim 34, wherein the surface is covered by a layer of material comprising a therapeutic substance.
36. The device of claim 22, the device being a stent comprising an inner surface opposite the outer surface and a side wall between the outer and inner surfaces, wherein the side wall has a roughness factor less than 40 nm.
37. The device of claim 22, wherein the asperities comprise tips having a shape selected from the group of (a) sharp, (b) rounded, (c) square or (d) a combination thereof.
38. The device of claim 22, wherein the roughness factor is between 50 nm and 50 μm.
39. The device of claim 29, wherein the sharp tips have a height between 0.1 μm and 10 μm.
40. The device of claim 30, wherein the layer is a first layer, further comprising a second layer of material overlaying a portion of the first layer.
41. The stent of claim 34, wherein the structure has an inner surface opposite an outer surface, and wherein the inner surface has a roughness factor less than 40 nm.
42. The stent of claim 34, wherein the roughness factor is greater than 100 nm.
43. The stent of claim 34, wherein the surface comprises an entire outer surface of the structure.
44. The stent of claim 34, wherein the surface comprises a portion of an outer surface of the structure in only a middle section of the stent.
45. The stent of claim 34, wherein the surface is covered by a material comprising a radioopaque substance.
46. The stent of claim 34, wherein the surface comprises asperities including sharp tips.
47. The stent of claim 46, wherein the sharp tips have a height between 0.1 μm and 10 μm.
48. The stent of claim 34, comprising an inner surface opposite an outer surface, and a side wall between the outer and inner surfaces, wherein the side wall has a roughness factor less than 40 nm.
49. The stent of claim 34, wherein the surface comprises asperities including tips having a shape selected from the group of (a) sharp, (b) rounded, (c) square or (d) a combination thereof.
50. The stent of claim 34, wherein the roughness factor is between 50 nm and 50 μm.
51. The stent of claim 35, wherein the layer is a first layer, further comprising a second layer of material overlaying a portion of the first layer.
52. An implantable medical device, comprising:
a surface including protrusions and indentations, the protrusions having a height; and
a coating material deposited on the surface so that the height of some of the protrusion is greater than the thickness of the material deposited on the surface.
53. The device of claim 52, wherein the coating material is a therapeutic substance.
54. The device of claim 52, wherein the protrusions include sharp tips.
55. The device of claim 54, wherein the sharp tips have a height between 0.1 μm and 10 μm.
56. The device of claim 52, wherein the protrusions and indentations form a roughened surface having a roughness factor greater than 40 nm.
57. The device of claim 52, wherein the protrusions and indentations form a roughened surface having a roughness factor between 50 nm and 50 μm.
58. The device of claim 52, wherein the protrusions include tips having a shape selected from the group of (a) sharp, (b) rounded, (c) square or (d) a combination thereof.
59. The device of claim 52, wherein the coating material is a first coating material, further comprising a second coating material overlaying a portion of the first coating material so that the protrusions are completely covered by the second coating material.
60. The device of claim 52, wherein the device is a stent or a graft.
US10/911,968 2000-09-28 2004-08-04 Surface features of an implantable medical device Abandoned US20050033411A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/911,968 US20050033411A1 (en) 2000-09-28 2004-08-04 Surface features of an implantable medical device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/675,092 US6805898B1 (en) 2000-09-28 2000-09-28 Surface features of an implantable medical device
US10/911,968 US20050033411A1 (en) 2000-09-28 2004-08-04 Surface features of an implantable medical device

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/675,092 Division US6805898B1 (en) 2000-09-28 2000-09-28 Surface features of an implantable medical device

Publications (1)

Publication Number Publication Date
US20050033411A1 true US20050033411A1 (en) 2005-02-10

Family

ID=33132093

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/675,092 Expired - Lifetime US6805898B1 (en) 2000-09-28 2000-09-28 Surface features of an implantable medical device
US10/911,968 Abandoned US20050033411A1 (en) 2000-09-28 2004-08-04 Surface features of an implantable medical device
US10/912,025 Expired - Fee Related US7335314B2 (en) 2000-09-28 2004-08-04 Method of making an implantable medical device

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/675,092 Expired - Lifetime US6805898B1 (en) 2000-09-28 2000-09-28 Surface features of an implantable medical device

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/912,025 Expired - Fee Related US7335314B2 (en) 2000-09-28 2004-08-04 Method of making an implantable medical device

Country Status (1)

Country Link
US (3) US6805898B1 (en)

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070073414A1 (en) * 2004-03-24 2007-03-29 Patrik Westerkull Assembly for controlling emptying of a female urine bladder, incontinence valve, and urine drainage assembly comprising the assembly
US20080243231A1 (en) * 2007-03-01 2008-10-02 Aiden Flanagan Medical device with a porous surface for delivery of a therapeutic agent
US20090005860A1 (en) * 2007-06-27 2009-01-01 Gale David C Method to fabricate a stent having selected morphology to reduce restenosis
US20090157167A1 (en) * 2007-12-18 2009-06-18 Bahler Clinton D Method of promoting cell proliferation and ingrowth by injury to the native tissue
US20100305682A1 (en) * 2006-09-21 2010-12-02 Cleveny Technologies Specially configured and surface modified medical device with certain design features that utilize the intrinsic properties of tungsten, zirconium, tantalum and/or niobium
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8057534B2 (en) 2006-09-15 2011-11-15 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
JP2015192919A (en) * 2009-02-02 2015-11-05 コーディス・コーポレイションCordis Corporation flexible stent design
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US10172729B2 (en) 2015-10-12 2019-01-08 Reflow Medical, Inc. Stents having protruding drug-delivery features and associated systems and methods

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959664B2 (en) * 1996-12-26 2011-06-14 Medinol, Ltd. Flat process of drug coating for stents
IT1289815B1 (en) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa ANGIOPLASTIC STENT AND RELATED PRODUCTION PROCESS
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7179289B2 (en) 1998-03-30 2007-02-20 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
AU2001269936A1 (en) * 2000-06-20 2002-01-02 Phycotransgenics, Llc Transgenic algae for delivering antigens to an animal
US6805898B1 (en) * 2000-09-28 2004-10-19 Advanced Cardiovascular Systems, Inc. Surface features of an implantable medical device
JP2006500115A (en) 2000-11-16 2006-01-05 マイクロスフエリツクス・エル・エル・シー Flexible and / or elastic seeds or strands for brachytherapy
US6913617B1 (en) * 2000-12-27 2005-07-05 Advanced Cardiovascular Systems, Inc. Method for creating a textured surface on an implantable medical device
US6663662B2 (en) * 2000-12-28 2003-12-16 Advanced Cardiovascular Systems, Inc. Diffusion barrier layer for implantable devices
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US6764505B1 (en) 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US8889169B2 (en) * 2001-05-11 2014-11-18 Exogenesis Corporation Drug delivery system and method of manufacturing thereof
US7666462B2 (en) * 2001-05-11 2010-02-23 Exogenesis Corporation Method of controlling a drug release rate
US7923055B2 (en) * 2001-05-11 2011-04-12 Exogenesis Corporation Method of manufacturing a drug delivery system
US7527803B2 (en) * 2001-08-16 2009-05-05 Purdue Research Foundation PLGA substrate with aligned and nano-sized surface structures and associated method
US7622129B1 (en) 2002-08-05 2009-11-24 Purdue Research Foundation Nano-structured polymers for use as implants
WO2003015836A1 (en) * 2001-08-16 2003-02-27 Purdue Research Foundation Material and method for promoting tissue growth
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7989018B2 (en) 2001-09-17 2011-08-02 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US7285304B1 (en) 2003-06-25 2007-10-23 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US8562664B2 (en) 2001-10-25 2013-10-22 Advanced Cardiovascular Systems, Inc. Manufacture of fine-grained material for use in medical devices
US6761680B2 (en) * 2001-11-02 2004-07-13 Richard A. Terwilliger Delivery system and method for interstitial radiation therapy using seed strands constructed with preformed strand housing
US7074291B2 (en) 2001-11-02 2006-07-11 Worldwide Medical Technologies, L.L.C. Delivery system and method for interstitial radiation therapy using strands constructed with extruded strand housings
US7060020B2 (en) 2001-11-02 2006-06-13 Ideamatrix, Inc. Delivery system and method for interstitial radiation therapy
US20030225451A1 (en) * 2002-01-14 2003-12-04 Rangarajan Sundar Stent delivery system, device, and method for coating
ATE495769T1 (en) 2002-07-12 2011-02-15 Cook Inc COATED MEDICAL DEVICE
EP1402849B2 (en) * 2002-09-20 2011-03-16 Abbott Laboratories Vascular Enterprises Limited Stent with rough surface and its manufacturing method
US7758636B2 (en) 2002-09-20 2010-07-20 Innovational Holdings Llc Expandable medical device with openings for delivery of multiple beneficial agents
CA2503489C (en) * 2002-10-25 2013-09-10 Essentia Biosystems, Inc. Modulation of zinc levels to improve tissue properties
US20040093056A1 (en) 2002-10-26 2004-05-13 Johnson Lianw M. Medical appliance delivery apparatus and method of use
US7875068B2 (en) 2002-11-05 2011-01-25 Merit Medical Systems, Inc. Removable biliary stent
US7959671B2 (en) 2002-11-05 2011-06-14 Merit Medical Systems, Inc. Differential covering and coating methods
US7637942B2 (en) 2002-11-05 2009-12-29 Merit Medical Systems, Inc. Coated stent with geometry determinated functionality and method of making the same
US7169178B1 (en) * 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US20050070989A1 (en) * 2002-11-13 2005-03-31 Whye-Kei Lye Medical devices having porous layers and methods for making the same
US20060121080A1 (en) 2002-11-13 2006-06-08 Lye Whye K Medical devices having nanoporous layers and methods for making the same
JP2006514848A (en) * 2002-11-13 2006-05-18 セタゴン インコーポレーティッド Medical device having porous layer and method for producing the same
US9770349B2 (en) * 2002-11-13 2017-09-26 University Of Virginia Patent Foundation Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation
US7964439B2 (en) * 2002-12-20 2011-06-21 The Trustees Of Princeton University Methods of fabricating devices by transfer of organic material
WO2004096085A2 (en) * 2003-03-27 2004-11-11 Purdue Research Foundation Nanofibers as a neural biomaterial
ATE526038T1 (en) 2003-03-28 2011-10-15 Innovational Holdings Llc IMPLANTABLE MEDICAL DEVICE WITH CONTINUOUS MEDIUM CONCENTRATION DISTANCE
US7637934B2 (en) 2003-03-31 2009-12-29 Merit Medical Systems, Inc. Medical appliance optical delivery and deployment apparatus and method
US6997862B2 (en) 2003-05-13 2006-02-14 Ideamatrix, Inc. Delivery system and method for interstitial radiation therapy using seed strands with custom end spacing
US7214383B2 (en) * 2003-06-16 2007-05-08 Bruce Alan Daniels Stent for delivery of drugs to the endothelium
US20070043332A1 (en) * 2003-07-10 2007-02-22 Galen (Chemiclas) Liimited Intravaginal drug delivery devices
US20050288773A1 (en) * 2004-01-22 2005-12-29 Glocker David A Radiopaque coating for biomedical devices
US8137397B2 (en) * 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
US9498563B2 (en) * 2004-04-23 2016-11-22 Boston Scientific Scimed, Inc. Medical articles having therapeutic-agent-containing regions formed from coalesced polymer particles
US20050251245A1 (en) * 2004-05-05 2005-11-10 Karl Sieradzki Methods and apparatus with porous materials
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US20060034884A1 (en) * 2004-08-10 2006-02-16 Stenzel Eric B Coated medical device having an increased coating surface area
EP1786363B1 (en) * 2004-08-13 2010-04-14 Setagon, Inc. Methods for making medical devices having nanoporous layers
US7901451B2 (en) * 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US8329202B2 (en) * 2004-11-12 2012-12-11 Depuy Products, Inc. System and method for attaching soft tissue to an implant
US8057543B2 (en) * 2005-01-28 2011-11-15 Greatbatch Ltd. Stent coating for eluting medication
US8221824B2 (en) * 2005-02-03 2012-07-17 Boston Scientific Scimed, Inc. Deforming surface of drug eluting coating to alter drug release profile of a medical device
ES2764992T3 (en) 2005-04-04 2020-06-05 Flexible Stenting Solutions Inc Flexible stent
US7799083B2 (en) * 2005-05-02 2010-09-21 Seaspine, Inc. Prosthesis for restoring motion in an appendage or spinal joint and an intervertebral spacer
US8343040B2 (en) 2005-05-04 2013-01-01 Olympus Endo Technology America Inc. Rotate-to-advance catheterization system
US8317678B2 (en) 2005-05-04 2012-11-27 Olympus Endo Technology America Inc. Rotate-to-advance catheterization system
US7780650B2 (en) * 2005-05-04 2010-08-24 Spirus Medical, Inc. Rotate-to-advance catheterization system
US8235942B2 (en) 2005-05-04 2012-08-07 Olympus Endo Technology America Inc. Rotate-to-advance catheterization system
US8414477B2 (en) 2005-05-04 2013-04-09 Olympus Endo Technology America Inc. Rotate-to-advance catheterization system
CA2609048C (en) * 2005-05-19 2014-01-21 Spirus Medical Inc. Rotate-to-advance catheterization system
US20060271170A1 (en) * 2005-05-31 2006-11-30 Gale David C Stent with flexible sections in high strain regions
US8187159B2 (en) 2005-07-22 2012-05-29 Biocompatibles, UK Therapeutic member including a rail used in brachytherapy and other radiation therapy
US7736293B2 (en) 2005-07-22 2010-06-15 Biocompatibles Uk Limited Implants for use in brachytherapy and other radiation therapy that resist migration and rotation
US7647687B2 (en) * 2005-09-14 2010-01-19 Boston Scientific Scimed, Inc. Method of manufacturing a stent
US7867176B2 (en) * 2005-12-27 2011-01-11 Cordis Corporation Variable stiffness guidewire
US20070156230A1 (en) 2006-01-04 2007-07-05 Dugan Stephen R Stents with radiopaque markers
US20070173925A1 (en) * 2006-01-25 2007-07-26 Cornova, Inc. Flexible expandable stent
US8574220B2 (en) 2006-02-28 2013-11-05 Olympus Endo Technology America Inc. Rotate-to-advance catheterization system
US8435229B2 (en) 2006-02-28 2013-05-07 Olympus Endo Technology America Inc. Rotate-to-advance catheterization system
US8828077B2 (en) 2006-03-15 2014-09-09 Medinol Ltd. Flat process of preparing drug eluting stents
US7785317B2 (en) 2006-03-29 2010-08-31 Codman & Shurtleff, Inc. Joined metal tubing and method of manufacture
US20070231363A1 (en) * 2006-03-29 2007-10-04 Yung-Ming Chen Coatings formed from stimulus-sensitive material
US7988611B2 (en) 2006-05-09 2011-08-02 Biocompatibles Uk Limited After-loader for positioning implants for needle delivery in brachytherapy and other radiation therapy
US8118859B2 (en) * 2006-05-26 2012-02-21 Codman & Shurtleff, Inc. Occlusion device combination of stent and mesh having offset parallelogram porosity
US20130325104A1 (en) 2006-05-26 2013-12-05 Abbott Cardiovascular Systems Inc. Stents With Radiopaque Markers
US8690938B2 (en) * 2006-05-26 2014-04-08 DePuy Synthes Products, LLC Occlusion device combination of stent and mesh with diamond-shaped porosity
US20080097620A1 (en) 2006-05-26 2008-04-24 Nanyang Technological University Implantable article, method of forming same and method for reducing thrombogenicity
US20080124372A1 (en) 2006-06-06 2008-05-29 Hossainy Syed F A Morphology profiles for control of agent release rates from polymer matrices
US8778376B2 (en) 2006-06-09 2014-07-15 Advanced Cardiovascular Systems, Inc. Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating
US7766935B2 (en) * 2006-06-12 2010-08-03 Codman & Shurtleff, Inc. Modified headpiece for hydraulic coil deployment system
US7670353B2 (en) * 2006-06-12 2010-03-02 Codman & Shurtleff, Inc. Modified headpiece for hydraulic coil deployment system
US8585732B2 (en) * 2006-06-14 2013-11-19 DePuy Synthes Products, LLC Retrieval device with sidewall grippers
US8535372B1 (en) 2006-06-16 2013-09-17 Abbott Cardiovascular Systems Inc. Bioabsorbable stent with prohealing layer
US20070299491A1 (en) * 2006-06-22 2007-12-27 Harshad Borgaonkar Drug-eluting coating on shocking coil of tachy lead and methods related thereto
US8128688B2 (en) 2006-06-27 2012-03-06 Abbott Cardiovascular Systems Inc. Carbon coating on an implantable device
US7740791B2 (en) * 2006-06-30 2010-06-22 Advanced Cardiovascular Systems, Inc. Method of fabricating a stent with features by blow molding
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
US7823263B2 (en) 2006-07-11 2010-11-02 Abbott Cardiovascular Systems Inc. Method of removing stent islands from a stent
US8016879B2 (en) 2006-08-01 2011-09-13 Abbott Cardiovascular Systems Inc. Drug delivery after biodegradation of the stent scaffolding
US20080091262A1 (en) * 2006-10-17 2008-04-17 Gale David C Drug delivery after biodegradation of the stent scaffolding
US20080057102A1 (en) * 2006-08-21 2008-03-06 Wouter Roorda Methods of manufacturing medical devices for controlled drug release
US8834554B2 (en) * 2006-08-22 2014-09-16 Abbott Cardiovascular Systems Inc. Intravascular stent
US8882826B2 (en) * 2006-08-22 2014-11-11 Abbott Cardiovascular Systems Inc. Intravascular stent
WO2008024712A2 (en) * 2006-08-22 2008-02-28 Abbott Cardiovascular Systems Inc. Intravascular stent
US20080215132A1 (en) * 2006-08-28 2008-09-04 Cornova, Inc. Implantable devices having textured surfaces and methods of forming the same
US7874976B1 (en) 2006-09-07 2011-01-25 Biocompatibles Uk Limited Echogenic strands and spacers therein
US7878964B1 (en) 2006-09-07 2011-02-01 Biocompatibles Uk Limited Echogenic spacers and strands
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
CN101663054B (en) * 2006-10-20 2013-08-07 生物传感器国际集团有限公司 Drug-delivery endovascular stent and method of use
US20080097591A1 (en) * 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
WO2008051867A2 (en) * 2006-10-20 2008-05-02 Elixir Medical Corporation Luminal prostheses and methods for coating thereof
US7832251B2 (en) * 2006-11-15 2010-11-16 Abbott Laboratories Patterned mold for medical device
CN101199873B (en) * 2006-12-14 2013-06-19 乐普(北京)医疗器械股份有限公司 Medicament elution instrument nanometer class colon washer machineole drug releasing structure and preparing method thereof
US8814930B2 (en) 2007-01-19 2014-08-26 Elixir Medical Corporation Biodegradable endoprosthesis and methods for their fabrication
KR20120106880A (en) 2007-01-21 2012-09-26 헤모텍 아게 Medical product for treating stenosis of body passages and for preventing threatening restenosis
US7824270B2 (en) * 2007-01-23 2010-11-02 C-Flex Bearing Co., Inc. Flexible coupling
WO2008092028A1 (en) 2007-01-25 2008-07-31 Tini Alloy Company Frangible shape memory alloy fire sprinkler valve actuator
US8584767B2 (en) 2007-01-25 2013-11-19 Tini Alloy Company Sprinkler valve with active actuation
US7575593B2 (en) * 2007-01-30 2009-08-18 Medtronic Vascular, Inc. Implantable device with reservoirs for increased drug loading
US20080206441A1 (en) * 2007-02-27 2008-08-28 Medtronic Vascular, Inc. Ion Beam Etching a Surface of an Implantable Medical Device
KR101387479B1 (en) * 2007-03-16 2014-04-21 엘지전자 주식회사 A method for processing image in mobile communication terminal and the mobile communication terminal
US8646444B2 (en) * 2007-03-27 2014-02-11 Electrolux Home Products, Inc. Glide rack
US20080249605A1 (en) * 2007-04-04 2008-10-09 Vipul Dave Bioabsorbable Polymer, Non-Bioabsorbable Metal Composite Stents
US20080249608A1 (en) * 2007-04-04 2008-10-09 Vipul Dave Bioabsorbable Polymer, Bioabsorbable Composite Stents
US8870755B2 (en) 2007-05-18 2014-10-28 Olympus Endo Technology America Inc. Rotate-to-advance catheterization system
ITBO20070436A1 (en) * 2007-06-22 2008-12-23 Azionaria Materiale Ospeda Lie METHOD FOR PRODUCING SURFACES FOR METALLIC MANUALS
DE102007029672A1 (en) * 2007-06-27 2009-01-02 Lzh Laserzentrum Hannover E.V. Implant and method for its production
US7955381B1 (en) 2007-06-29 2011-06-07 Advanced Cardiovascular Systems, Inc. Polymer-bioceramic composite implantable medical device with different types of bioceramic particles
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US8007674B2 (en) * 2007-07-30 2011-08-30 Tini Alloy Company Method and devices for preventing restenosis in cardiovascular stents
US7988723B2 (en) 2007-08-02 2011-08-02 Flexible Stenting Solutions, Inc. Flexible stent
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US20090287302A1 (en) * 2008-05-16 2009-11-19 Chameleon Scientific Corporation Polymer coated spinulose metal surfaces
US20100298925A1 (en) * 2007-10-31 2010-11-25 Chameleon Scientific Corporation Spinulose metal surfaces
US7833266B2 (en) 2007-11-28 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
KR101409458B1 (en) * 2007-11-28 2014-06-19 삼성전자주식회사 Portable communication terminal having an aromatic function and apparatus for charging communication terminal having the same
US20090204203A1 (en) * 2008-02-07 2009-08-13 Medtronic Vascular, Inc. Bioabsorbable Stent Having a Radiopaque Marker
US20110081399A1 (en) * 2008-03-13 2011-04-07 Enbio Limited Surface modification of nitinol
WO2009126550A2 (en) * 2008-04-08 2009-10-15 Med Institute, Inc. Surface structure of a component of a medical device and a method of forming the surface structure
US20090263456A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
US9364349B2 (en) * 2008-04-24 2016-06-14 Surmodics, Inc. Coating application system with shaped mandrel
US8206636B2 (en) 2008-06-20 2012-06-26 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US8206635B2 (en) 2008-06-20 2012-06-26 Amaranth Medical Pte. Stent fabrication via tubular casting processes
DE102008040356A1 (en) * 2008-07-11 2010-01-14 Biotronik Vi Patent Ag Stent with biodegradable stent struts and drug depots
US7951193B2 (en) 2008-07-23 2011-05-31 Boston Scientific Scimed, Inc. Drug-eluting stent
WO2010011843A1 (en) 2008-07-25 2010-01-28 Cook Incorporated Balloon catheter and method for making the same
US20100036482A1 (en) * 2008-08-07 2010-02-11 Exogenesis Corporation Drug delivery system and method of manufacturing thereof
EP2326356B1 (en) 2008-08-07 2017-10-11 Exogenesis Corporation Medical device for bone implant and method for producing such a device
CN102196826A (en) * 2008-08-27 2011-09-21 波士顿科学医学有限公司 Medical devices having inorganic coatings for therapeutic agent delivery
JP5530361B2 (en) * 2008-09-17 2014-06-25 テルモ株式会社 Stent
US9149376B2 (en) 2008-10-06 2015-10-06 Cordis Corporation Reconstrainable stent delivery system
EP2352460B1 (en) * 2008-11-06 2019-01-02 Biosensors International Group, Ltd. Surface textured implants
GB0821927D0 (en) * 2008-12-01 2009-01-07 Ucl Business Plc Article and method of surface treatment of an article
US20100183523A1 (en) * 2009-01-22 2010-07-22 Wagner Richard E Dental composition and method
WO2010091106A1 (en) * 2009-02-03 2010-08-12 Abbott Cardiovascular Systems Inc. Improved laser cutting system
WO2010091100A1 (en) 2009-02-03 2010-08-12 Abbott Cardiovascular Systems Inc. Multiple beam laser system for forming stents
WO2010091093A1 (en) * 2009-02-03 2010-08-12 Abbott Cardiovascular Systems Inc. Improved laser cutting process for forming stents
US20100209475A1 (en) * 2009-02-19 2010-08-19 Biomet Manufacturing Corp. Medical implants having a drug delivery coating
US20100227697A1 (en) * 2009-03-04 2010-09-09 C-Flex Bearing Co., Inc. Flexible coupling
US20100233227A1 (en) * 2009-03-10 2010-09-16 Boston Scientific Scimed, Inc. Medical devices having carbon drug releasing layers
US8454707B2 (en) * 2009-04-03 2013-06-04 University Of Maryland Biomedical implantable material and methods of producing the same
US20100272773A1 (en) * 2009-04-24 2010-10-28 Boston Scientific Scimed, Inc. Use of Drug Polymorphs to Achieve Controlled Drug Delivery From a Coated Medical Device
CA3186201A1 (en) 2009-05-20 2010-11-25 Lyra Therapeutics, Inc. Self-expandable medical device comprising polymeric strands and coatings thereon
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
WO2011005421A2 (en) 2009-07-10 2011-01-13 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
EP2453938B1 (en) 2009-07-17 2015-08-19 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
WO2011040218A1 (en) * 2009-09-30 2011-04-07 テルモ株式会社 Stent
EP2338534A2 (en) * 2009-12-21 2011-06-29 Biotronik VI Patent AG Medical implant, coating method and implantation method
CN102113927A (en) * 2009-12-30 2011-07-06 微创医疗器械(上海)有限公司 Self-expanded stent
US8808353B2 (en) 2010-01-30 2014-08-19 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds having a low crossing profile
US8568471B2 (en) 2010-01-30 2013-10-29 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
US8562670B2 (en) * 2010-04-01 2013-10-22 Abbott Cardiovascular Systems Inc. Implantable prosthesis with depot retention feature
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8556511B2 (en) 2010-09-08 2013-10-15 Abbott Cardiovascular Systems, Inc. Fluid bearing to support stent tubing during laser cutting
US20120095396A1 (en) 2010-10-18 2012-04-19 Boston Scientific Scimed, Inc. Drug Eluting Medical Device Utilizing Bioadhesives
JP2014522273A (en) * 2011-05-20 2014-09-04 ユニヴァーシティ オブ セントラル フロリダ リサーチ ファウンデーション,インコーポレーテッド Surface modifier for electromagnetic field response adjustment
US9121237B2 (en) 2011-07-28 2015-09-01 Baker Hughes Incorporated Methods of coating wellbore tools and components having such coatings
US8726483B2 (en) 2011-07-29 2014-05-20 Abbott Cardiovascular Systems Inc. Methods for uniform crimping and deployment of a polymer scaffold
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US20130041406A1 (en) * 2011-08-10 2013-02-14 Brian W. Bear Surgical staple with localized adjunct coating
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
MX351261B (en) 2012-06-01 2017-10-06 Surmodics Inc Apparatus and method for coating balloon catheters.
US10124197B2 (en) 2012-08-31 2018-11-13 TiNi Allot Company Fire sprinkler valve actuator
US11040230B2 (en) 2012-08-31 2021-06-22 Tini Alloy Company Fire sprinkler valve actuator
ES2654189T3 (en) 2012-09-12 2018-02-12 Boston Scientific Scimed, Inc. Anti-migration stent adhesive coating
KR101419019B1 (en) * 2012-09-28 2014-07-11 신경민 Plastic stent insertion device Plastic stent insertion device
US20140121747A1 (en) 2012-10-25 2014-05-01 Boston Scientific Scimed, Inc. Stent having a tacky silicone coating to prevent stent migration
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
US9283350B2 (en) 2012-12-07 2016-03-15 Surmodics, Inc. Coating apparatus and methods
EP3427766B1 (en) 2013-08-08 2020-09-23 Boston Scientific Scimed, Inc. Dissolvable or degradable adhesive polymer to prevent stent migration
US9610164B2 (en) * 2014-02-03 2017-04-04 Biomet Manufacturing, Llc Stiffening structure in a prosthetic member
US9730819B2 (en) 2014-08-15 2017-08-15 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9259339B1 (en) 2014-08-15 2016-02-16 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9480588B2 (en) 2014-08-15 2016-11-01 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9855156B2 (en) * 2014-08-15 2018-01-02 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
WO2016073597A1 (en) * 2014-11-06 2016-05-12 Boston Scientific Scimed, Inc. Tracheal stent
US9999527B2 (en) 2015-02-11 2018-06-19 Abbott Cardiovascular Systems Inc. Scaffolds having radiopaque markers
US9700443B2 (en) 2015-06-12 2017-07-11 Abbott Cardiovascular Systems Inc. Methods for attaching a radiopaque marker to a scaffold
US11622872B2 (en) 2016-05-16 2023-04-11 Elixir Medical Corporation Uncaging stent
ES2873887T3 (en) 2016-05-16 2021-11-04 Elixir Medical Corp Stent release
US10531941B2 (en) 2016-11-09 2020-01-14 Boston Scientific Scimed, Inc. Stent including anti-migration capabilities
CN109922760B (en) * 2016-11-10 2022-03-04 美敦力瓦斯科尔勒公司 Drug-filled stent for preventing vascular micro-injury and manufacturing method thereof
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11058564B2 (en) * 2019-02-27 2021-07-13 Vactronix Scientific Llc Stent and method of making same
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices

Citations (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3586999A (en) * 1968-10-16 1971-06-22 Rca Corp Field-excited semiconductor laser which uses a uniformly doped single crystal
US3855638A (en) * 1970-06-04 1974-12-24 Ontario Research Foundation Surgical prosthetic device with porous metal coating
US4006270A (en) * 1973-02-08 1977-02-01 W. R. Grace & Co. Solid curable polyene compositions and method of coating therewith
US4101984A (en) * 1975-05-09 1978-07-25 Macgregor David C Cardiovascular prosthetic devices and implants with porous systems
US4321711A (en) * 1978-10-18 1982-03-30 Sumitomo Electric Industries, Ltd. Vascular prosthesis
US4355426A (en) * 1975-05-09 1982-10-26 Macgregor David C Porous flexible vascular graft
US4374669A (en) * 1975-05-09 1983-02-22 Mac Gregor David C Cardiovascular prosthetic devices and implants with porous systems
US4693721A (en) * 1984-10-17 1987-09-15 Paul Ducheyne Porous flexible metal fiber material for surgical implantation
US4729871A (en) * 1985-06-21 1988-03-08 Hiroshi Kawaguchi Process for preparing porous metal plate
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) * 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US5059211A (en) * 1987-06-25 1991-10-22 Duke University Absorbable vascular stent
US5163958A (en) * 1989-02-02 1992-11-17 Cordis Corporation Carbon coated tubular endoprosthesis
US5163952A (en) * 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5234456A (en) * 1990-02-08 1993-08-10 Pfizer Hospital Products Group, Inc. Hydrophilic stent
US5246530A (en) * 1990-04-20 1993-09-21 Dynamet Incorporated Method of producing porous metal surface
US5328471A (en) * 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US5370684A (en) * 1986-12-12 1994-12-06 Sorin Biomedica S.P.A. Prosthesis of polymeric material coated with biocompatible carbon
US5370682A (en) * 1993-04-26 1994-12-06 Meadox Medicals, Inc. Solid woven tubular prosthesis
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5433909A (en) * 1992-03-13 1995-07-18 Atrium Medical Corporation Method of making controlled porosity expanded polytetrafluoroethylene products
US5437834A (en) * 1992-10-08 1995-08-01 Kyocera Corporation Porous living body repairing member, and a method of imparting elasticity to it
US5441515A (en) * 1993-04-23 1995-08-15 Advanced Cardiovascular Systems, Inc. Ratcheting stent
US5443500A (en) * 1989-01-26 1995-08-22 Advanced Cardiovascular Systems, Inc. Intravascular stent
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5507815A (en) * 1991-06-17 1996-04-16 Cycam, Inc. Random surface protrusions on an implantable device
US5514154A (en) * 1991-10-28 1996-05-07 Advanced Cardiovascular Systems, Inc. Expandable stents
US5522894A (en) * 1984-12-14 1996-06-04 Draenert; Klaus Bone replacement material made of absorbable beads
US5527337A (en) * 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
US5569295A (en) * 1993-12-28 1996-10-29 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5571187A (en) * 1992-02-27 1996-11-05 Zimmer, Inc. Implant having a metallic porous surface
US5605693A (en) * 1991-10-18 1997-02-25 Seare, Jr.; William J. Methods of making a porous device
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5607463A (en) * 1993-03-30 1997-03-04 Medtronic, Inc. Intravascular medical device
US5630840A (en) * 1993-01-19 1997-05-20 Schneider (Usa) Inc Clad composite stent
US5632779A (en) * 1989-07-25 1997-05-27 Smith & Nephew, Inc. Zirconium oxide and zirconium nitride coated vascular grafts
US5697967A (en) * 1992-03-19 1997-12-16 Medtronic, Inc. Drug eluting stent
US5700286A (en) * 1994-12-13 1997-12-23 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5707385A (en) * 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US5713949A (en) * 1996-08-06 1998-02-03 Jayaraman; Swaminathan Microporous covered stents and method of coating
US5725567A (en) * 1990-02-28 1998-03-10 Medtronic, Inc. Method of making a intralumenal drug eluting prosthesis
US5741429A (en) * 1991-09-05 1998-04-21 Cardia Catheter Company Flexible tubular device for use in medical applications
US5746691A (en) * 1997-06-06 1998-05-05 Global Therapeutics, Inc. Method for polishing surgical stents
US5749880A (en) * 1995-03-10 1998-05-12 Impra, Inc. Endoluminal encapsulated stent and methods of manufacture and endoluminal delivery
US5755771A (en) * 1994-11-03 1998-05-26 Divysio Solutions Ulc Expandable stent and method of delivery of same
US5759192A (en) * 1994-11-28 1998-06-02 Advanced Cardiovascular Systems, Inc. Method and apparatus for direct laser cutting of metal stents
US5766710A (en) * 1994-06-27 1998-06-16 Advanced Cardiovascular Systems, Inc. Biodegradable mesh and film stent
US5769883A (en) * 1991-10-04 1998-06-23 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5782907A (en) * 1995-07-13 1998-07-21 Devices For Vascular Intervention, Inc. Involuted spring stent and graft assembly and method of use
US5788558A (en) * 1995-11-13 1998-08-04 Localmed, Inc. Apparatus and method for polishing lumenal prostheses
US5800512A (en) * 1996-01-22 1998-09-01 Meadox Medicals, Inc. PTFE vascular graft
US5824455A (en) * 1990-09-26 1998-10-20 Canon Kabushiki Kaisha Processing method and apparatus
US5824049A (en) * 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US5843289A (en) * 1996-01-22 1998-12-01 Etex Corporation Surface modification of medical implants
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US5856814A (en) * 1995-08-02 1999-01-05 Canon Kk Driving method for display apparatus
US5876448A (en) * 1992-05-08 1999-03-02 Schneider (Usa) Inc. Esophageal stent
US5879398A (en) * 1995-02-14 1999-03-09 Zimmer, Inc. Acetabular cup
US5902266A (en) * 1994-09-12 1999-05-11 Cordis Corporation Method for delivering a liquid solution to the interior wall surface of a vessel
US5928279A (en) * 1996-07-03 1999-07-27 Baxter International Inc. Stented, radially expandable, tubular PTFE grafts
US5945029A (en) * 1996-09-03 1999-08-31 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Ceramic monofilament or multifilament fiber and processes for their production and use
US5951881A (en) * 1996-07-22 1999-09-14 President And Fellows Of Harvard College Fabrication of small-scale cylindrical articles
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
US6010529A (en) * 1996-12-03 2000-01-04 Atrium Medical Corporation Expandable shielded vessel support
US6027779A (en) * 1993-08-18 2000-02-22 W. L. Gore & Associates, Inc. Thin-wall polytetrafluoroethylene tube
US6033582A (en) * 1996-01-22 2000-03-07 Etex Corporation Surface modification of medical implants
US6069295A (en) * 1996-05-10 2000-05-30 Isotis B.V. Implant material
US6071296A (en) * 1995-12-07 2000-06-06 Lashinski; Robert D. Stent for improved transluminal deployment
US6095817A (en) * 1999-02-24 2000-08-01 Sulzer Calcitek Inc. Dental implant having multiple textured surfaces
US6099561A (en) * 1996-10-21 2000-08-08 Inflow Dynamics, Inc. Vascular and endoluminal stents with improved coatings
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6136369A (en) * 1996-05-10 2000-10-24 Isotis B.V. Device for incorporation and release of biologically active agents
US6143370A (en) * 1997-08-27 2000-11-07 Northeastern University Process for producing polymer coatings with various porosities and surface areas
US6203732B1 (en) * 1998-07-02 2001-03-20 Intra Therapeutics, Inc. Method for manufacturing intraluminal device
US6206915B1 (en) * 1998-09-29 2001-03-27 Medtronic Ave, Inc. Drug storing and metering stent
US6240616B1 (en) * 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6287628B1 (en) * 1999-09-03 2001-09-11 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6287337B1 (en) * 1996-12-03 2001-09-11 Atrium Medical Corporation Multi-stage prosthesis
US6312459B1 (en) * 1999-06-30 2001-11-06 Advanced Cardiovascular Systems, Inc. Stent design for use in small vessels
US6379381B1 (en) * 1999-09-03 2002-04-30 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6395326B1 (en) * 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US6419692B1 (en) * 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6558733B1 (en) * 2000-10-26 2003-05-06 Advanced Cardiovascular Systems, Inc. Method for etching a micropatterned microdepot prosthesis
US6610087B1 (en) * 1999-11-16 2003-08-26 Scimed Life Systems, Inc. Endoluminal stent having a matched stiffness region and/or a stiffness gradient and methods for providing stent kink resistance
US6638302B1 (en) * 1996-12-30 2003-10-28 Sorin Biomedica Cardio S.P.A. Stent for angioplasty and associated production process
US6645241B1 (en) * 1992-07-08 2003-11-11 Ernst Peter Strecker Endoprosthesis that can be percutaneously implanted in the patient's body
US20030215564A1 (en) * 2001-01-18 2003-11-20 Heller Phillip F. Method and apparatus for coating an endoprosthesis
US6783543B2 (en) * 2000-06-05 2004-08-31 Scimed Life Systems, Inc. Intravascular stent with increasing coating retaining capacity
US6805898B1 (en) * 2000-09-28 2004-10-19 Advanced Cardiovascular Systems, Inc. Surface features of an implantable medical device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63160645A (en) 1986-12-24 1988-07-04 オリンパス光学工業株式会社 Body stay tube
AU4191989A (en) 1988-08-24 1990-03-23 Marvin J. Slepian Biodegradable polymeric endoluminal sealing
JPH0314516A (en) 1989-06-09 1991-01-23 Kyoji Sei Structure containing percutaneous absorption drug impregnated therein
US5342348A (en) 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
DE4336705C2 (en) 1993-10-27 1996-11-28 Hoffmann Elektrokohle Sliding contact element and method for connecting an electrical connecting conductor to a sliding contact element
US6165210A (en) 1994-04-01 2000-12-26 Gore Enterprise Holdings, Inc. Self-expandable helical intravascular stent and stent-graft
US5554569A (en) 1994-06-06 1996-09-10 Motorola, Inc. Method and apparatus for improving interfacial adhesion between a polymer and a metal
JPH08213026A (en) 1994-11-28 1996-08-20 Katayama Tokushu Kogyo Kk Metallic porous body for battery electrode substrate, battery plate, and manufacture thereof
CA2566929C (en) 1995-03-10 2009-04-21 Bard Peripheral Vascular, Inc. Endoluminal encapsulated stent and methods of manufacture and endoluminal delivery
AU6423796A (en) * 1995-08-29 1997-03-06 Johnson & Johnson Professional, Inc. Bone prosthesis with protected coating for penetrating bone intergrowth
JP3677329B2 (en) 1995-09-25 2005-07-27 新東工業株式会社 Filter for treating carbon-based fine particles in exhaust gas and carbon-based fine particle processing apparatus using the same
ZA9710342B (en) 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
US5980972A (en) 1996-12-20 1999-11-09 Schneider (Usa) Inc Method of applying drug-release coatings
JPH11299901A (en) 1998-04-16 1999-11-02 Johnson & Johnson Medical Kk Stent and its manufacture

Patent Citations (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3586999A (en) * 1968-10-16 1971-06-22 Rca Corp Field-excited semiconductor laser which uses a uniformly doped single crystal
US3855638A (en) * 1970-06-04 1974-12-24 Ontario Research Foundation Surgical prosthetic device with porous metal coating
US4006270A (en) * 1973-02-08 1977-02-01 W. R. Grace & Co. Solid curable polyene compositions and method of coating therewith
US4355426A (en) * 1975-05-09 1982-10-26 Macgregor David C Porous flexible vascular graft
US4101984A (en) * 1975-05-09 1978-07-25 Macgregor David C Cardiovascular prosthetic devices and implants with porous systems
US4374669A (en) * 1975-05-09 1983-02-22 Mac Gregor David C Cardiovascular prosthetic devices and implants with porous systems
US4459252A (en) * 1975-05-09 1984-07-10 Macgregor David C Method of forming a small bore flexible vascular graft involving eluting solvent-elutable particles from a polymeric tubular article
US4321711A (en) * 1978-10-18 1982-03-30 Sumitomo Electric Industries, Ltd. Vascular prosthesis
US4693721A (en) * 1984-10-17 1987-09-15 Paul Ducheyne Porous flexible metal fiber material for surgical implantation
US5522894A (en) * 1984-12-14 1996-06-04 Draenert; Klaus Bone replacement material made of absorbable beads
US4729871A (en) * 1985-06-21 1988-03-08 Hiroshi Kawaguchi Process for preparing porous metal plate
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665B1 (en) * 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US5370684A (en) * 1986-12-12 1994-12-06 Sorin Biomedica S.P.A. Prosthesis of polymeric material coated with biocompatible carbon
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US5059211A (en) * 1987-06-25 1991-10-22 Duke University Absorbable vascular stent
US5527337A (en) * 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
US5306286A (en) * 1987-06-25 1994-04-26 Duke University Absorbable stent
US4886062A (en) * 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US5443500A (en) * 1989-01-26 1995-08-22 Advanced Cardiovascular Systems, Inc. Intravascular stent
US5163958A (en) * 1989-02-02 1992-11-17 Cordis Corporation Carbon coated tubular endoprosthesis
US5632779A (en) * 1989-07-25 1997-05-27 Smith & Nephew, Inc. Zirconium oxide and zirconium nitride coated vascular grafts
US5234456A (en) * 1990-02-08 1993-08-10 Pfizer Hospital Products Group, Inc. Hydrophilic stent
US5328471A (en) * 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US5725567A (en) * 1990-02-28 1998-03-10 Medtronic, Inc. Method of making a intralumenal drug eluting prosthesis
US5246530A (en) * 1990-04-20 1993-09-21 Dynamet Incorporated Method of producing porous metal surface
US5163952A (en) * 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5824455A (en) * 1990-09-26 1998-10-20 Canon Kabushiki Kaisha Processing method and apparatus
US5507815A (en) * 1991-06-17 1996-04-16 Cycam, Inc. Random surface protrusions on an implantable device
US5741429A (en) * 1991-09-05 1998-04-21 Cardia Catheter Company Flexible tubular device for use in medical applications
US5769883A (en) * 1991-10-04 1998-06-23 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5605693A (en) * 1991-10-18 1997-02-25 Seare, Jr.; William J. Methods of making a porous device
US5514154A (en) * 1991-10-28 1996-05-07 Advanced Cardiovascular Systems, Inc. Expandable stents
US5766238A (en) * 1991-10-28 1998-06-16 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5571187A (en) * 1992-02-27 1996-11-05 Zimmer, Inc. Implant having a metallic porous surface
US5433909A (en) * 1992-03-13 1995-07-18 Atrium Medical Corporation Method of making controlled porosity expanded polytetrafluoroethylene products
US5697967A (en) * 1992-03-19 1997-12-16 Medtronic, Inc. Drug eluting stent
US5876448A (en) * 1992-05-08 1999-03-02 Schneider (Usa) Inc. Esophageal stent
US6645241B1 (en) * 1992-07-08 2003-11-11 Ernst Peter Strecker Endoprosthesis that can be percutaneously implanted in the patient's body
US5437834A (en) * 1992-10-08 1995-08-01 Kyocera Corporation Porous living body repairing member, and a method of imparting elasticity to it
US5492768A (en) * 1992-10-08 1996-02-20 Kyocera Corporation Porous living body repairing member, and a method of imparting elasticity to it
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5630840A (en) * 1993-01-19 1997-05-20 Schneider (Usa) Inc Clad composite stent
US5607463A (en) * 1993-03-30 1997-03-04 Medtronic, Inc. Intravascular medical device
US5441515A (en) * 1993-04-23 1995-08-15 Advanced Cardiovascular Systems, Inc. Ratcheting stent
US5370682A (en) * 1993-04-26 1994-12-06 Meadox Medicals, Inc. Solid woven tubular prosthesis
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5624411A (en) * 1993-04-26 1997-04-29 Medtronic, Inc. Intravascular stent and method
US6027779A (en) * 1993-08-18 2000-02-22 W. L. Gore & Associates, Inc. Thin-wall polytetrafluoroethylene tube
US5916234A (en) * 1993-12-28 1999-06-29 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5569295A (en) * 1993-12-28 1996-10-29 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5766710A (en) * 1994-06-27 1998-06-16 Advanced Cardiovascular Systems, Inc. Biodegradable mesh and film stent
US5902266A (en) * 1994-09-12 1999-05-11 Cordis Corporation Method for delivering a liquid solution to the interior wall surface of a vessel
US5755771A (en) * 1994-11-03 1998-05-26 Divysio Solutions Ulc Expandable stent and method of delivery of same
US5707385A (en) * 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US5759192A (en) * 1994-11-28 1998-06-02 Advanced Cardiovascular Systems, Inc. Method and apparatus for direct laser cutting of metal stents
US5700286A (en) * 1994-12-13 1997-12-23 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5879398A (en) * 1995-02-14 1999-03-09 Zimmer, Inc. Acetabular cup
US5749880A (en) * 1995-03-10 1998-05-12 Impra, Inc. Endoluminal encapsulated stent and methods of manufacture and endoluminal delivery
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5824049A (en) * 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US5782907A (en) * 1995-07-13 1998-07-21 Devices For Vascular Intervention, Inc. Involuted spring stent and graft assembly and method of use
US5856814A (en) * 1995-08-02 1999-01-05 Canon Kk Driving method for display apparatus
US5788558A (en) * 1995-11-13 1998-08-04 Localmed, Inc. Apparatus and method for polishing lumenal prostheses
US6071296A (en) * 1995-12-07 2000-06-06 Lashinski; Robert D. Stent for improved transluminal deployment
US5800512A (en) * 1996-01-22 1998-09-01 Meadox Medicals, Inc. PTFE vascular graft
US5843289A (en) * 1996-01-22 1998-12-01 Etex Corporation Surface modification of medical implants
US6033582A (en) * 1996-01-22 2000-03-07 Etex Corporation Surface modification of medical implants
US6136369A (en) * 1996-05-10 2000-10-24 Isotis B.V. Device for incorporation and release of biologically active agents
US6069295A (en) * 1996-05-10 2000-05-30 Isotis B.V. Implant material
US5928279A (en) * 1996-07-03 1999-07-27 Baxter International Inc. Stented, radially expandable, tubular PTFE grafts
US5951881A (en) * 1996-07-22 1999-09-14 President And Fellows Of Harvard College Fabrication of small-scale cylindrical articles
US5713949A (en) * 1996-08-06 1998-02-03 Jayaraman; Swaminathan Microporous covered stents and method of coating
US5945029A (en) * 1996-09-03 1999-08-31 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Ceramic monofilament or multifilament fiber and processes for their production and use
US6099561A (en) * 1996-10-21 2000-08-08 Inflow Dynamics, Inc. Vascular and endoluminal stents with improved coatings
US6010529A (en) * 1996-12-03 2000-01-04 Atrium Medical Corporation Expandable shielded vessel support
US6287337B1 (en) * 1996-12-03 2001-09-11 Atrium Medical Corporation Multi-stage prosthesis
US6638302B1 (en) * 1996-12-30 2003-10-28 Sorin Biomedica Cardio S.P.A. Stent for angioplasty and associated production process
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US6240616B1 (en) * 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5746691A (en) * 1997-06-06 1998-05-05 Global Therapeutics, Inc. Method for polishing surgical stents
US6143370A (en) * 1997-08-27 2000-11-07 Northeastern University Process for producing polymer coatings with various porosities and surface areas
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
US6203732B1 (en) * 1998-07-02 2001-03-20 Intra Therapeutics, Inc. Method for manufacturing intraluminal device
US6206915B1 (en) * 1998-09-29 2001-03-27 Medtronic Ave, Inc. Drug storing and metering stent
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) * 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6095817A (en) * 1999-02-24 2000-08-01 Sulzer Calcitek Inc. Dental implant having multiple textured surfaces
US6312459B1 (en) * 1999-06-30 2001-11-06 Advanced Cardiovascular Systems, Inc. Stent design for use in small vessels
US6379381B1 (en) * 1999-09-03 2002-04-30 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6287628B1 (en) * 1999-09-03 2001-09-11 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6610087B1 (en) * 1999-11-16 2003-08-26 Scimed Life Systems, Inc. Endoluminal stent having a matched stiffness region and/or a stiffness gradient and methods for providing stent kink resistance
US6395326B1 (en) * 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US6783543B2 (en) * 2000-06-05 2004-08-31 Scimed Life Systems, Inc. Intravascular stent with increasing coating retaining capacity
US6805898B1 (en) * 2000-09-28 2004-10-19 Advanced Cardiovascular Systems, Inc. Surface features of an implantable medical device
US6558733B1 (en) * 2000-10-26 2003-05-06 Advanced Cardiovascular Systems, Inc. Method for etching a micropatterned microdepot prosthesis
US20030215564A1 (en) * 2001-01-18 2003-11-20 Heller Phillip F. Method and apparatus for coating an endoprosthesis

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US20070073414A1 (en) * 2004-03-24 2007-03-29 Patrik Westerkull Assembly for controlling emptying of a female urine bladder, incontinence valve, and urine drainage assembly comprising the assembly
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US8057534B2 (en) 2006-09-15 2011-11-15 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US20100305682A1 (en) * 2006-09-21 2010-12-02 Cleveny Technologies Specially configured and surface modified medical device with certain design features that utilize the intrinsic properties of tungsten, zirconium, tantalum and/or niobium
US8769794B2 (en) * 2006-09-21 2014-07-08 Mico Innovations, Llc Specially configured and surface modified medical device with certain design features that utilize the intrinsic properties of tungsten, zirconium, tantalum and/or niobium
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US8715339B2 (en) 2006-12-28 2014-05-06 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8070797B2 (en) * 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US20080243231A1 (en) * 2007-03-01 2008-10-02 Aiden Flanagan Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US20090005860A1 (en) * 2007-06-27 2009-01-01 Gale David C Method to fabricate a stent having selected morphology to reduce restenosis
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7815687B2 (en) 2007-12-18 2010-10-19 Med Institute, Inc. Method of promoting cell proliferation and ingrowth by injury to the native tissue
US20090157167A1 (en) * 2007-12-18 2009-06-18 Bahler Clinton D Method of promoting cell proliferation and ingrowth by injury to the native tissue
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
JP2015192919A (en) * 2009-02-02 2015-11-05 コーディス・コーポレイションCordis Corporation flexible stent design
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US10172729B2 (en) 2015-10-12 2019-01-08 Reflow Medical, Inc. Stents having protruding drug-delivery features and associated systems and methods
US10258487B2 (en) 2015-10-12 2019-04-16 Reflow Medical, Inc. Stents having protruding drug-delivery features and associated systems and methods
US11253379B2 (en) 2015-10-12 2022-02-22 Reflow Medical, Inc. Stents having protruding drug-delivery features and associated systems and methods

Also Published As

Publication number Publication date
US6805898B1 (en) 2004-10-19
US20050033412A1 (en) 2005-02-10
US7335314B2 (en) 2008-02-26

Similar Documents

Publication Publication Date Title
US7335314B2 (en) Method of making an implantable medical device
US6451373B1 (en) Method of forming a therapeutic coating onto a surface of an implantable prosthesis
US6913617B1 (en) Method for creating a textured surface on an implantable medical device
JP5139438B2 (en) Drug delivery endovascular stent and method of use
EP1517713B1 (en) Stent coatings with sustained drug release rate
US7455876B2 (en) Apparatus and method for depositing a coating onto a surface of a prosthesis
US6254632B1 (en) Implantable medical device having protruding surface structures for drug delivery and cover attachment
US6979346B1 (en) System and method for improved stent retention
US6506437B1 (en) Methods of coating an implantable device having depots formed in a surface thereof
EP1684821B1 (en) Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
EP1214108B1 (en) A porous prosthesis and a method of depositing substances into the pores
WO2002026162A2 (en) A method of loading a substance onto an implantable device
US6379381B1 (en) Porous prosthesis and a method of depositing substances into the pores
US20080243240A1 (en) Biodegradable Metal Barrier Layer for a Drug-Eluting Stent
US20040211362A1 (en) System for coating a stent
US20070027523A1 (en) Method of treating vascular disease at a bifurcated vessel using coated balloon
WO2001091918A1 (en) An apparatus and method for forming a coating onto a surface of a prosthesis
US7824729B2 (en) Methods for coating an implantable device
JP2012179476A (en) Drug delivery endovascular stent and method of use
US20080206441A1 (en) Ion Beam Etching a Surface of an Implantable Medical Device
US8114153B2 (en) Endoprostheses
US20100125329A1 (en) Pseudoelastic stents having a drug coating and a method of producing the same
US20070110280A1 (en) Methods for Determining Coating Thickness of a Prosthesis

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION